1. ALL - Biology
2. AML - Biology 1
3. AML - Clinical 1
4. AML - Clinical 2
5. Clinical SCD and other anemias
6. CLL - Clinical studies
7. CLL - Translational Research
8. CML - Biology 1
9. CML - Clinical 1
10. Health economics
11. Hodgkin Lymphoma
12. Infectious diseases, supportive care
13. MDS - Clinical 1
14. MDS and bone marrow failure syndromes incl. PNH - Biology
15. MPN - Biology
16. MPN - Clinical 1
17. Multiple myeloma - Biology 1
18. Multiple myeloma - Translational and clinical studies 1
19. Non-Hodgkin Lymphoma - Clinical 1
20. Non-Hodgkin Lymphoma - Clinical 2
21. Non-Hodgkin Lymphoma - Biology
22. Platelets 1
23. Red blood cells and iron; physiology and disease (anemia) - Clinical
24. Signalling, transcription and apoptosis
25. Stem cell transplantation - Clinical 1
26. Stem cell transplantation - Clinical 2
27. Thrombosis and vascular biology 1
28. Transfusion medicine
29. CLL - Microenvironmental interactions
30. Granulocytes (oral)
31. Hodgkin Lymphoma (oral)
32. Molecular Markers in ALL
33. MPN - Biology (oral)
34. Multiple Myeloma - Biology
35. Red blood cells - Biology
36. Stem cell transplantation - Clinical 1 (oral)
37. Therapeutic targets in acute leukemia
38. Presidential
39. AML Therapeutics
40. Bleeding & Thrombosis (oral)
41. Clinical studies in Multiple Myeloma 1
42. CML - Biology
43. Drug Responsiveness in Acute leukemias
44. MDS / MPN - Clinical / Biology
45. Non-Hodgkin Lymphoma - Clinical 1 (oral)
46. Novel CLL genetics - Clinical implications
47. Stem cell transplantation - Clinical 2 (oral)
48. ALL - Clinical
49. AML - Biology 2
50. AML - Clinical 3
51. Bleeding & Thrombosis
52. Cellular immunotherapy and vaccination
53. CLL - Immune triggering and microenvironmental interactions
54. CML - Biology 2
55. CML - Clinical 2
56. Cytogenetics and molecular diagnostics
57. Drug resistance and pharmacology
58. Granulocytes
59. Hematopoiesis
60. MDS - Clinical 2
61. MPN - Clinical 2
62. Multiple myeloma - Biology 2
63. Multiple myeloma - Translational and clinical studies 2
64. Multiple myeloma - Translational and clinical studies 3
65. Non-Hodgkin Lymphoma - Clinical 3
66. Non-Hodgkin Lymphoma - Biology & Clinical
67. Novel therapeutics, targeted therapies and gene therapy
68. Platelets 2
69. Quality of Life
70. Red blood cells and iron; physiology and disease (anemia) - Biology
71. Stem cell transplantation - Clinical 3
72. Stem cell transplantation - Clinical 4
73. Stem cell transplantation - Experimental
74. Thrombosis and vascular biology 2
75. ALL Therapeutics
76. Cellular immunotherapy and vaccination (oral)
77. CML - Clinical
78. Lymphoid leukemogenesis
79. MDS - Clinical
80. MPN - Clinical
81. Myeloid Leukemogenesis
82. Non-Hodgkin Lymphoma - Biology
83. Platelets
84. Clinical studies in Multiple Myeloma 2
85. CLL - Clinical studies (oral)
86. Hematopoiesis (oral)
87. MDS - Biology
88. Molecular markers in AML
89. Non-Hodgkin Lymphoma - Clinical 2 (oral)
90. Novel therapeutics
91. Red blood cells - Clinical
92. Stem cell transplantation - Experimental (oral)
93. OXIDATIVE STRESS INFLUENCE HYDROXYMETHYLATION STATUS IN ACUTE LYMPHOBLASTIC
LEUKEMIA CELLS IN VITRO
94. EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1, VASCULAR ENDOTHELIAL
GROWTH FACTOR RECEPTOR-2 AND FMS-LIKE TYROSINE KINASE-3 RECEPTOR IN CHILDHOOD ACUTE
LYMPHOBLASTIC LEUKEMIA
95. TNFRSF13B/TACI AND TNFRSF13C/BAFFR EXPRESSION IN ACUTE LYMPHOBLASTIC LEUKEMIA
96. PAIRED IMMUNOPHENOTYPE COMPARISON OF DIAGNOSIS AND RELAPSE SAMPLES IN B-LINEAGE
ACUTE LYMPHOBLASTIC LEUKEMIA
97. GSTM1 GENOTYPE AS A RISK MODIFIER OF MDR1 C3435T - INDUCED RISK SUSCEPTIBILITY TO
PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
98. CAN WE KNOW MORE ABOUT ACUTE LEUKEMIA IN CHILDREN THROUGH EPIDEMIOLOGY?
99. CHARACTERIZATION OF MDM2/P53 AXIS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
100. DETERMINATION OF CYTOTOXIC AND APOPTOTIC EFFECTS OF CAFFEIC ACID PHENETHYL ESTER
AND GOSSYPOL IN COMBINATION WITH FLUDARABINE AT A MOLECULAR LEVEL IN ACUTE
LYMPHOBLASTIC LEUKEMIA CELLS
101. CLINICAL SIGNIFICANCE OF LOW SENSITIVITY PROBES IN MRD ANALYSIS OF ADULT ALL
PATIENTS
102. PROGNOSTIC VALUE OF DAY 15 BLAST COUNT IN CHILDREN WITH ACUTE LYMPHOBLASTIC
LEUKEMIA TREATED WITH ALL-BFM 95 PROTOCOL
103. ACUTE LYMPHOBLASTIC LEUKEMIA IN THE ELDERLY: A TOUGH ONE
104. NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (TLBL/ALL): PRELIMINARY RESULTS OF A SINGLE CENTRE EXPERIENCE
105. ACUTE MIXED LINEAGE LEUKEMIA TREATMENT OUTCOME: A 5 YEARS SINGLE INSTITUTE
EXPERIENCE
106. THE LONG TERM RESULTS OF CHILDHOOD ALL AT TWO CENTERS FROM TURKEY: 15 YEARS OF
EXPERIENCE WITH ALL BFM 95 PROTOCOL
107. ZAP-70 EXPRESSION IN ACUTE LYMPHOBLASTIC LEUKEMIA:RELATION TO PATIENTS'
PROGNOSIS AND CYTOGENETIC RISK GROUPS
108. SERUM LEVELS OF MULTIPLE CYTOKINES AND ADHESION MOLECULES IN PATIENTS WITH NEWLY
DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA AND IN HEALTHY SUBJECTS
109. MICRO-RNA PROFILE OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
110. IMMUNOPHENOTYPIC ANALYSIS OF T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA. A CD5
PERSPECTIVE
111. ROLE OF ALLOGRAFTING IN ACUTE LYMPHOBLASTIC LEUKEMIA: A 12 YEAR EXPERIENCE
112. FAVORABLE OUTCOME FOR ADOLESCENTS AND YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA TREATED WITH EORTC 58951
113. LONG-TERM RESULTS OF EORTC 58951 PROTOCOL FOR CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKEMIA IN THE SOUTH OF TUNISIA
114. ADOLESCENT AND YOUNG ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: TUNISIAN MONOCENTRIC
EXPERIENCE
115. EVALUATION OF SURVIVAL RATES OF OUR PATIENTS WITH CHILDHOOD ACUTE LYMPHOBLASTIC
LEUKEMIA:SINGLE CENTER EXPERIENCE
116. IMPACT OF RISK FACTORS ON LONG-TERM OUTCOME IN 125 ADULT ACUTE LYMPHOBLASTIC
117. INFLUENCE OF SERUM CORTISOL LEVEL TO COLONY-FORMING EFFICIENCY OF BONE MARROW
STROMAL FIBROBLASTS AT CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
118. EARLY T CELL PRECURSOR LEUKEMIA: INMUNOPHENOTYPE AND CLINICAL CHARACTERISTICS
OF A RARE AND AGGRESSIVE ALL-T SUBTYPE. EXPERIENCE IN ONE CENTER
119. CMV REACTIVATION IN ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE IN TREATMENT WITH
DASATINIB
120. ACUTE LYMPHOBLASTIC LEUKEMIA OF HIGH AND INTERMEDIATE RISK. SINGLE CENTER
EXPERIENCE SINCE 2000
121. CYTOCHROME P450 3A4(CYP3A4) GENE POLYMORPHISM AMONG EGYPTIAN CHILDREN WITH
ACUTE LYMPHOBLASTIC LEUKEMIA
122. THE SERUM TRAIL AND TRAIL LIGAND ON THE APOPITOTIC PATHWAY IN CHILDHOOD ACUTE
LEUKEMIAS
123. LOW PLATELET COUNTS AS A PROGNOSTIC MARKER IN ALL TREATMENT IN PLACE OF MRD IN
COUNTRIES WITH LIMITED FINANCIAL RESOURCES
124. TREATMENT EFFICACY IN PATIENTS WITH ALL UNDER 1 YEAR ENROLLED IN A CLINICAL
TRIAL MLL-BABY IS STRONGLY ASSOCIATED WITH TREATING CLINIC EXPERIENCE IN INFANTS CARE
125. INFECTIONS DURING INDUCTION OF REMISSION IN CHILDREN WITH ACUTE LYMPHOBLASTIC
LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA- COMPARATIVE STUDY
126. PROLIFERATION OF ACUTE MYELOGENOUS BLASTS AS EFFECT OF DIFFERENT CYTOKINES CAN
BE USED TO IDENTIFIED PATIENT AND CYTOKINE SUBSETS ALSO BY GENE EXPRESSION PROFILES
127. DIFFERENTIAL EXPRESSION OF NEW METNASE (SETMAR) TRANSCRIPT VARIANTS IN
HEMATOLOGICAL CANCERS- INCREASE IN AML PATIENTS
128. NEWLY DIAGNOSED ADULT AML AND MPAL PATIENTS FREQUENTLY SHOW CLONAL RESIDUAL
HEMATOPOIESIS
129. MINIMAL RESIDUAL DISEASE AND CLEARANCE OF LEUKEMIC BLASTS IN ACUTE MYELOID
LEUKEMIA: TIMING AND CUT-OFF VALUES BETWEEN MFC AND WT1
130. FLOW CYTOMETRIC ASSESSMENT OF HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1
(HENT1) EXPRESSION IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
131. CELL CYCLE MODELING OFFERS A PLATFORM TO OPTIMIZE COMBINATION OF CYTARABINE AND
FLT3 INHIBITORS IN ACUTE MYELOID LEUKEMIA
132. EXPRESSION OF PIM-2 GENE, BAD AND 4E-BP1 PROTEIN IS INCREASED IN PATIENTS WITH
AML AND ALL AND CORRELATES WITH COMPLETE REMISSION RATE, OVERALL SURVIVAL AND
APOPTOSIS RATE.
133. FLUVASTATIN CAN INCREASE APOPTOSIS INDUCED BY VALPROIC ACID AND ALL-TRANSRETINOIC ACID IN FLT3-ITD-POSITIVE AML CELLS
134. OVEREXPRESSION OF WILMS TUMOR GENE 1 (WT1) IN ACUTE PROMYELOCYTIC LEUKEMIA.
135. ALU-REPEAT REGIONS ARE NOT HYPER- AND DEMETHYLATION TARGET POINTS .
136. CLINICAL AND BIOLOGICAL CHARACTERISTICS OF ACUTE MYELOID LEUKEMIA WITH ABERRANT
EXPRESSION OF CD56+CD11B+
137. REDUCED EXPRESSION OF 90 KD HEAT SHOCK PROTEIN (HSP90) IS RELATED TO PU.1 AND
PML-RARA COMPLEX IN ACUTE PROMYELOCYTIC LEUKEMIA
138. ACUTE LEUKAEMIA WITH MULTILINEAL DYSPLASIA - CLINICAL AND IMMUNOPHENOTYPICAL
FEATURES - 5 YEARS EXPERIENCE OF A SINGLE CENTER
139. ARE MUTATIONS IN THE IDH2 GENE SUITABLE MOLECULAR MARKERS FOR MRD MONITORING IN
AML PATIENTS?
140. ASSESSMENT OF WT1 TRANSCRIPT REDUCTION FOR PROGNOSTIC IMPLICATION IN ACUTE
MYELOID LEUKEMIA PATIENTS
141. ABERRANT EXPRESSION OF LYMPHOID-ASSOCIATED ANTIGENS IN ACUTE MYELOID LEUKEMIA:
INCIDENCE AND CLINICOBIOLOGICAL IMPLICATIONS
142. AML CELLS SENSITIVE TO THE NOVEL TYROSINE KINASE INHIBITOR AKN-028 SHOW A HIGHER
OVERALL TYROSINE KINASE ACTIVITY THAN MORE RESISTANT SAMPLES
143. A NOVEL APPROACH IN THE DEFINITION OF "BLAST GATE" IN AML USING CD66 AND CD14 AS
MATURATION INDICES
144. GLOBAL GENE ARRAY ANALYSES TO IDENTIFY BIOMARKERS ASSOCIATED WITH CLINICAL
OUTCOME IN ACUTE MYELOID LEUKEMIA
145. TREATMENT WITH G-CSF AND AMD3100 DIMINISH THE CLONOGENIC CAPACITY OF PRIMARY
ACUTE MYELOID LEUKEMIA BLASTS IN VITRO
146. CLINICAL AND BIOLOGICAL CHARACTERISTICS OF IDH1 AND 2 MUTATIONS IN ACUTE MYELOID
LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE (NC-AML) IN SERBIA
147. DOWNREGULATION OF PROGRAMMED CELL DEATH LIGAND-1 PROTEIN INHIBITS
MIGRATION,ADHESION AND INVASION OF LEUKEMIA HL-60 CELLS
148. THE TRIM FAMILY UBIQUITIN LIGASE TRIM32 PROMOTES CELL DIFFERENTIATION AND
SUPPRESSES CELL PROLIFERATION OF HUMAN AN APL CELL LINE VIA RETINOIC ACID RECEPTOR
ALPHA-MEDIATED TRANSCRIPTION
149. EXPRESSION LEVELS OF WT1 AND NPM1 AND NOVEL NONSPECIFIC MARKERS AS TOOLS FOR
EVALUATING MINIMAL RESIDUAL DISEASE IN AML
150. INCIDENCE AND CLINICAL FEATURES OF PATIENTS WITH AML1-ETO, CBFB-MYH11 AND PMLRARA TRANSCRIPTS IN THERAPY-RELATED COMPARED TO DE NOVO ACUTE MYELOID LEUKEMIAS IN A
COHORT OF 449 BULGARIAN PATIENTS
151. UNFAVORABLE PROGNOSTIC IMPACT OF WT1 MUTATIONS IN PEDIATRIC ACUTE MYELOID
LEUKEMIA IN KOREA
152. MANAGEMENT OF FIT OLDER PATIENTS WITH AML : MAJOR IMPACT OF CYTOGENETICS
153. A RARE VARIANT TRANSLOCATION IN APL
154. DNA METHYLTRANSFERASE FAMILY GENES MUTATIONAL STATUS IN CANIS FAMILIARIS AML: A
POTENTIAL MODEL FOR THE DISEASE IN PEDIATRIC PATIENTS
155. ANALYSIS OF ACTIVITY OF MATRIX METALLOPROTEINASES MMP-2 AND MMP9 IN BONE MARROW
PLASMA OF PATIENTS WITH ACUTE MYELOID LEUKEMIA
156. CORRELATIONS AMONG CFU-GM GROWTH PATTERNS AND ACUTE LEUKEMIA WHO-2008 ENTITIES
157. CLINICAL SIGNIFICANCE OF COMMON LEUKEMIA GENE MUTATIONS IN PATIENTS WITH ACUTE
PROMYELOCYTIC LEUKEMIA
158. TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA DURING PREGNANCY
159. IMPACT OF MRD STATUS PRIOR TO HSCT IN PEDIATRIC AML
160. IMPACT OF CD200 EXPRESSION IN ACUTE MYELOID LEUKEMIA
161. ANTI-TUMOR VACCINATION IN COMBINATION WITH MODIFIED DONOR LYMPHOCYTE INFUSION
FOR AN AML RESISTANT PATIENT WITH EARLY EXTRAMEDULLAR RELAPSES
162. MYELOID MORPHOLOGY AND THE NUMBER OF CO-EXPRESSED LYMPHOID-ASSOCIATED ANTIGENS
CORRELATE WITH POORER CLINICAL BEHAVIOUR IN CBF-POSITIVE ACUTE MYELOID LEUKAEMIAS
163. DECREASED SERUM RETINOL-BINDING PROTEIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
164. PERCENTAGE AND/OR ABSOLUTE LYMPHOCYTE COUNT AT DIAGNOSIS: PROGNOSTIC IMPACT IN
ACUTE MYELOID LEUKEMIA (AML)
165. CD56 EXPRESSION IN ACUTE PROMYELOCYTIC LEUKEMIA – A PREDICTIVE INDICATOR OF
RELAPSE?
166. TREATMENT WITH AZACITIDINE INCREASES OVERALL SURVIVAL, REDUCES INFECTIONS AND
HOSPITALIZATIONS IN ELDERLY PATIENTS WITH ACUTE LEUKEMIA COMPARED WITH INTENSIVE
CHEMOTHERAPY: A MONOCENTRIC STUDY
167. AMBULATORY CARE OF PATIENTS RECEIVING CONSOLIDATION CHEMOTHERAPY FOR ACUTE
MYELOID LEUKAEMIA : A FEASIBLE AND SAFE OPTION FOR SELECTED PATIENTS
168. FLAG-IDA : A HIGHLY EFFECTIVE SALVAGE REGIMEN IN PRIMARY REFRACTORY ACUTE
MYELOID LEUKEMIA
169. TREATMENT OUTCOME OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) - A SINGLE
CENTRE EXPERIENCE
170. TREATMENT OF MOLECULAR RELAPSE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
171. CYTARABINE PLUS IDARUBICIN AS INDUCTION THERAPY FOR UNTREATED ADULT PATIENTS
WITH ACUTE MYELOID LEUKEMIA. A SINGLE CENTER RETROSPECTIVE ANALYSIS OF 141 PATIENTS.
172. EARLY DETECTION OF SERUM GALACTOMANNAN ANTIGEN IN HEMATOLOGIC MALIGNANCIES:
IMPACT OF A LABORATORY ASSAY IN ASPERGILLUS INFECTION MORTALITY RATE
173. SECONDARY ACUTE MYELOID LEUKEMIA – FIRST LINE TREATMENT WITH CYTARABINE,
DAUNORUBICIN AND CYCLOSPORINE, A PORTUGUESE HOSPITAL’S EXPERIENCE
174. CD117 EXPRESSION IS ASSOCIATED WITH IMPROVED EVENT AND OVERALL SURVIVAL IN
PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH AIDA BASED REGIMEN
175. THREE CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIAS (CBF-AML) IN A SINGLE PATIENT
176. HDAC AND AMSACRINE FOR TREATMENT OF REFRACTORY AND RELAPSE ACUTE MYELOID
LEUKEMIA: A SINGLE CENTRE RETROSPECTIVE STUDY
177. CD96 AS A LEUKEMIA STEM CELL-SPECIFIC MARKER AND A FACTOR FOR PROGNOSIS
EVALUATION IN LEUKEMIA
178. STUDY OF THE GM-CSF GENE EXPRESSION AND ANTI GM-CSF AUTOANTIBODIES IN RELATION
TO DISEASE BEHAVIOR AND OUTCOME IN AML/MDS CASES
179. NO MODIFIED ANTI-INFLAMMATORY AND ANTIVIRAL COMPOUNDS AGAINST ACUTE MYELOIDE
LEUKEMIA; FROM CELL LINE TO PATIENT BLOOD
180. RESULTS OF >60 AML UNTREATED PATIENTS THERAPY IN DEPENDENCY OF QUALIFICATION TO
RISK AND INDUCTION INTENSITY GROUPS. RETROSPECTIVE STUDY.
181. TRANSFUSION IRON INTAKE IN TRANSPLANT ELIGIBLE PATIENTS WITH DE NOVO ACUTE
MYELOID LEUKEMIA: RETROSPECTIVE ANALYSIS OF IRON LOAD AT THE END OF CHEMOTHERAPY
PROGRAM AND BEFORE TRANSPLANTATION
182. RED BLOOD CELL ENCAPSULATING ASPARAGINASE IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA UNFIT FOR INTENSIVE CHEMOTHERAPY: A PROSPECTIVE PHASE IIB STUDY
183. MAINTENANCE THERAPY WITH CEPLENE® (HISTAMINE DIHYDROCHLORIDE) AND PROLEUKIN S®
(IL-2) LEADS TO ACTIVATION OF NK CELLS BUT ALSO EXPANSION OF T REGULATORY CELLS IN
AML
184. THE PROGNOSTIC IMPACT OF ABERRANT ANTIGEN EXPRESSION IN ACUTE LEUKEMIAS
185. PREDICTION OF CLONAL EVOLUTION UNRESPONSIVENESS TO THERAPY BY “EX VIVO”
CHEMOSENSITIVITY ASSAY IN A CASE OF ACUTE MYELOID LEUKEMIA
186. THE COMPARISON OF TOXICITY AND OUTCOMES OF THE INDUCTION CHEMOTHERAPY DAC (DNR,
ARAC, 2CDA) AND IAC (DNR REPLACED BY IDARUBICINE) IN THE ACUTE MYELOID LEUKAEMIA
(AML) PATIENTS. RETROSPECTIVE STUDY
187. SALVAGE WITH VERY HIGH DOSE CYTARABINE FOR RELAPSED/REFRACTORY AML IN THE
SETTING OF INTENSIFIED ANTHRACYCLINE INDUCTION AND POST STEM-CELL TRANSPLANTATION –
CLINICAL EFFICACY WITH ACCEPTABLE TOXICITY
188. CLINICAL COURSE OF ACUTE PROMYELOCYTIC LEUKEMIA: SINGLE-CENTER REPORT FROM A
DEVELOPING COUNTRY
189. THE EXPRESSION AND SIGNIFICANCE OF PD-L1 AND BCL-2 IN CHILDREN WITH ACUTE
LEUKEMIA
190. PROGNOSTIC VALUE OF MICRO RNA92A IN ACUTE MYEOID LEUKAEMIA
191. CONSOLIDATION CHEMOTERAPY WITH HIGH DOSE CYTARABINE FOLLOWED BY ALLOGENEIC HSCT
IN DE NOVO ACUTE MYELOID LEUKEMIA PATIENTS: RESULTS FROM A SINGLE CENTRE EXPERIENCE
ACCORDING TO DIFFERENCE RISK CLASSES
192. INFLUENCE OF FLT3/ITD MUTATION ON OUTCOME OF PATIENTS WITH DE NOVO ACUTE MYELOID
LEUKEMIA: A SINGLE CENTRE EXPERIENCE
193. THE EFFECTIVENESS OF INTENSIVE CHEMOTHERAPY TO THE ELDERLY ACUTE MYELOGENOUS
LEUKEMIA PATIENTS
194. IMMUNOPHENOTYPE DISTINCTION BETWEEN ACUTE PROMYELOCITIC LEUKEMIA AND HLA-DR-CD34
NEGATIVE ACUTE MYELOD LEUKEMIA: SINGLE CENTER EXPERIENCE
195. HYDROXYUREA (HU) ASSOCIATED TO SUPPORTIVE THERAPY AS CONSERVATIVE APPROACH IS
STILL A VALID OPTION FOR TREATING ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA (AML)
196. EVALUATION OF FEBRILE NEUTROPENIC EPISODES IN ACUTE MYELOID LEUKEMIA PATIENTS
197. PROGNOSTIC IMPLICATIONS OF BIOLOGICAL PARAMETERS IN THE DIAGNOSIS OF ACUTE
MYELOGENOUS LEUKEMIA. SINGLE INSTITUTION EXPERIENCE.
198. TUMOR FORMING PLASMACYTOID DENDRITIC CELLS ASSOCIATED WITH MYELOID NEOPLASM OR
BLASTIC PLASMOCYTOID DENDRITIC NEOPLASM? A DIAGNOSTIC CHALLENGE: LITERATURE REVIEW
AND CASE REPORT
199. ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS NOT CONSIDERED FIT FOR INTENSIVE
TREATMENT; AZACITIDINE, LOW DOSE CYTARABINE AND ETOPOSID COMBINATION EXPERIENCE FROM
A SINGLE CENTER
200. POSSIBILITY OF MOLECULAR REMISSION OBTAINING WITH NK AND T-CELLS RESTORATION
USING AUTOLOGOUS LYMPHOCYTES INFUSIONS AND IL2 IN RELAPSED ACUTE MYELOID LEUKEMIA
PATIENTS
201. THE CLINICAL AND THERAPEUTIC FEATURES OF ACTUE PROMYELOCYTIC LEUKEMIA IN
CHILDREN.
202. ACUTE MYELOID LEUKEMIA WITH FLT3-ITD AND COMPLETE ANDROGEN INSENSITIVITY
SYNDROME (MORRIS SYNDROME) –A CASE REPORT
203. CLINICAL RELEVANCE OF THROMBOSPONDIN RECEPTOR (CD36) EXPRESSION IN EGYPTIAN DE
NOVO ADULT ACUTE MYELOID LEUKEMIA
204. LEUKEMIC TRANSFORMATION OF MULTIPOTENT HEMATOPOIETIC PROGENITOR CELL WITH
T(4;11)(Q21:Q23) , MLL-AF9 FUSION PRODUCT AND LINEAGE SWITCH FROM B ACUTE
LYMPHOBLASTIC TO ACUTE MONOBLASTIC LEUKEMIA (AML
205. PROGNOSTIC SIGNIFICANCE RBC TRANSFUSIONS’ VOLUME INFUSED DURING THE FIRST
INDUCTION CHEMOTHERAPY TO PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA (AML)
206. CONCOMITANT OCCURRENCE OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM AND ACUTE
MYELOID LEUKAEMIA AFTER LENALIDOMIDE TREATMENT FOR DEL (5Q) MYELODYSPLASTIC SYNDROME:
A COINCIDENCE OR MORE?
207. THE USE OF AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNFIT FOR
INTENSIVE TREATMENT OR RESISTANT TO CHEMOTHERAPY
208. MULTIPLE INVOLVED SITES OF EXTRAMEDULLARY MEGAKARYOBLASTIC LEUKEMIA IN A
CHILD
209. STUDY OF ANGIOGENESIS ON LYMPH NODES OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
210. UBLITUXIMAB (TG-1101), A NOVEL ANTI-CD20 MONOCLONAL ANTIBODY, DISPLAYS MARKED IN
VITRO ACTIVITY IN LOW-CD20 EXPRESSING TUMORS
211. PHOSPHORYLATION OF ROR1 RECEPTOR TYROSINE KINASE AT TYROSINE 641, 646 AND SERINE
652 RESIDUES: THE IMPACT ON THE SURVIVAL OF LEUKEMIC CELLS OF PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKEMIA
212. THE REPERTOIRE OF HEAVY CHAIN IMMUNOGLOBULIN GENES IN B-CELL CHRONIC LYMPHOCYTIC
LEUKEMIA IN UKRAINE AND RUSSIA
213. THE HDAC INHIBITOR TRICHOSTATIN A INDUCES EFFECTIVE CELL KILL IN CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL).
214. REDUCED EXPRESSION OF TOLL-LIKE RECEPTOR 4 IN B-CHRONIC LYMPHOCYTIC LEUKEMIA
PATIENTS WITH AUTOIMMUNE COMPLICATIONS
215. IMMUNE CO-STIMULATION (BY CD40L) IS NOT SUFFICIENT TO INDUCE DIFFERENTIATION OF
CLL B-CELLS INTO IMMUNOGLOBULIN SECRETING CELLS
216. IMMUNOGLOBULIN GENE REARRANGEMENTS IN ASIAN PATIENTS WITH CHRONIC LYMPHOCYTIC
LEUKEMIA
217. ABERRANT EXPRESSION OF TOLL-LIKE RECEPTORS HIGHLIGHTS IMMUNE DEREGULATION WITH
SERIOUS CLINICAL CONSEQUENCES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
218. IN VITRO EFFICACY OF PARA-NITRIC OXIDE DONATING ACETYLIC SALICYLIC ACID TOWARDS
LYMPHOMA CELL LINES AND PRIMARY CHRONIC LYMPHOCYTIC LEUKEMIA CELLS HARBORING TP53
MUTATIONS OR DELETION 17P.
219. INCIDENCE AND PROGNOSTIC SIGNIFICANCE OF TCL-1 ONCOGENE IN CHRONIC LYMPHOCYTIC
LEUKEMIA
220. COMBINED PATTERNS OF IGHV REPERTOIRE AND CYTOGENETIC/MOLECULAR ALTERATIONS IN
MONOCLONAL B LYMPHOCYTOSIS VERSUS CHRONIC LYMPHOCYTIC LEUKEMIA
221. VEGF AND BFGF SINGLE-NUCLEOTIDE POLYMORPHISMS IN CHRONIC LYMPHOCYTIC LEUKEMIA:
IMPACT ON SUSCEPTIBILITY
222. ASSOCIATION BETWEEN THE MDM2 SNP309 POLYMORPHISM AND CLINICAL OUTCOME IN CHRONIC
LYMPHOCYTIC LEUKEMIA PATIENTS WITH UNMUTATED IGHV GENES
223. COMPARISON OF DIFFERENT RQ-PCR DESIGN STRATEGIES FOR MINIMAL RESIDUAL DISEASE
EVALUATION IN LYMPHOPROLIFERATIVE DISORDERS: CORRELATION BETWEEN IMMUNOGLOBULIN GENE
MUTATION LOAD AND RQ-PCR PERFORMANCE
224. IMPACT OF THE BIOLOGICAL AND CLINICAL FEATURES OF THE DISEASE ON THE REAL LIFE
OF THE CLL PATIENTS. A RETROSPECTIVE SINGLE CENTRE STUDY.
225. COMPARISON OF THE PI3K-DELTA INHIBITORS TGR-1202 AND GS-1101 IN INDUCING
CYTOTOXICITY AND INHIBITING PHOSPHORYLATION OF AKT IN CLL CELLS IN VITRO
226. POLYMORPHISM OF APOPTOSIS REGULATORY AND GROWTH FACTOR GENES IN PATIENTS WITH
CHRONIC LYMPHOCYTIC LEUKEMIA
227. FACTORS THAT MAY INFLUENCE THE KINETICS OF B LYMPHOCYTE DEPLETION IN RELAPSED
CLL PATIENTS TREATED WITH OFATUMUMAB – A SINGLE CENTRE EXPERIENCE
228. POSSIBLE MODIFYING ROLE OF PDE4D SNP83 POLYMORPHISM FOR IGHV REPERTOIRE IN CLL
PATIENTS
229. CELL SURFACE CD20 ANTIGEN EXPRESSION ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA
230. DESCRIPTION OF A FAVORABLE GROUP OF PATIENTS WITH CD5(+) MONOCLONAL B-CELL
LYMPHOCYTOSIS AND CHRONIC LYMPHOCYTIC LEUKEMIA RAI-0
231. CHEMOIMMUNOTHERAPY WITH RITUXIMAB AND LOW-DOSE ORAL FLUDARABINE AND
CYCLOPHOSPHAMIDE (R-FC-LOW DOSE OS) AS INITIAL TREATMENT FOR ELDERLY PATIENTS WITH
CHRONIC LYMPHOCYTIC LEUKEMIA
232. EFFICACY AND SAFETY OF RITUXIMAB AND HIGH-DOSE DEXAMETHASONE (R-DEX) IN THE
TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
233. REDUCTION IN IL-33 PLASMA LEVELS MIGHT BE INVOLVED IN T-CELL DYSREGULATION IN
CHRONIC LYMPHOCYTIC LEUKEMIA
234. THE EFFICACY AND SAFETY OF FIRST-LINE TREATMENTS FOR CHRONIC LYMPHOCYTIC
LEUKEMIA - A SYSTEMATIC REVIEW OF CLINICAL EVIDENCE
235. NEW ANALYSIS STRATEGIES MAKE FLOW CYTOMETRY MORE RELIABLE IN THE CLASSIFICATION
OF B-CELL CHRONIC LYMPHATIC LEUKEMIA
236. THE DIAGNOSTIC VALUE OF CD123 IN HCL AND OTHER B-CELL DISORDER WITH HAIRY
LYMPHOCYTES SINGLE CENTER EXPERIENCE
237. THE PROGNOSTIC VALUE OF THYMIDINE KINASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC
LEUKEMIA IN THE VARIOUS TYPES OF MODERN THERAPY
238. AUTOIMMUNITY AND CHRONIC LYMPHOCYTIC LEUKEMIA
239. VEMURAFENIB IS HIGHLY ACTIVE IN ADVANCED HAIRY-CELL LEUKEMIA: A REPORT OF TWO
CASES
240. AN OPEN-LABEL, SINGLE-ARM, PHASE I STUDY TO ASSESS SAFETY AND EFFECT OF
OFATUMUMAB ON B-CELL COUNTS, COMPLEMENT, AND CYTOKINES/CHEMOKINES IN PATIENTS WITH
REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
241. MULTIVARIABLE MODEL CONSISTED OF CLINICAL AND BIOLOGICAL MARKERS FOR TIME TO
FIRST TREATMENT IN CLL PATIENTS: PRELIMINARY RESULTS FROM SINGLE CENTRE EXPERIENCE
242. CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): EPIDEMIOLOGY, COMORBIDITIES AND TREATMENT
PREFERENCE IN DAILY CLINICAL PRACTICE
243. INTEGRATION OF AUTOMATED MORPHOLOGICAL FEATURES RESOLVES A DISTINCT GROUP OF
ATYPICAL CHRONIC LYMPHOCYTIC LEUKEMIAS WITH CHROMOSOMAL ABERRATIONS
244. SMALL LYMPHOCYTIC LYMPHOMA/ CHRONIC LYMPHOCYTIC LEUKEMIA : A RETROSPECTIVE
SURVEY OF PROGNOSIS FACTORS
245. RITUXIMAB IN COMBINATION WITH CLADRIBINE IN HAIRY CELL LEUKEMIA (HCL)
246. CHOLESTEROL LEVELS IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC LYMPHOCYTIC LEUKEMIA
247. THE ASSOCIATION OF FLUDARABINE AND CYCLOPHOSPHAMIDE AS FRONT LINE TREATMENT IN
CHRONIC LYMPHOCYTIC LEUKEMIA: HAS IT STILL A ROLE IN THE IMMUNE THERAPY ERA?
248. BCL-XL EXPRESSION AS A POTENTIAL PROGNOSTIC PARAMETER IN CHRONIC MYELOID
LEUKEMIA
249. BCR-ABL KINASE DOMAIN MUTATION FREQUENCY IN CHRONIC MYELOID LEUKEMIA (CML)
PATIENTS RESISTANT TO IMATINIB THERAPY
250. LOWER INCIDENCE OF CML IN O BLOOD GROUP AND SECRETOR INDIVIDUALS
251. BCR-ABL1 GENOMIC MOLECULAR CHARACTERIZATION IN CHILDREN WITH CML: DESCRIPTION
AND INTEREST FOR MOLECULAR FOLLOW-UP
252. IDENTIFICATION OF IL-6-174G/C PROMOTER POLYMORPHISM IN CHRONIC MYELOID LEUKEMIA
253. CREATION OF A RESOURCE GROUP ON "GENOMICS IN THE CLINIC IN LOW RESOURCE
SETTINGS": AN EXAMPLE USING A LONGITUDINAL STUDY OF A CML CASE
254. WHOLE EXOME SEQUENCING ANALYSIS IN CHRONIC MYELOID LEUKEMIA
255. MESENCHYMAL STEM CELLS FROM CHRONIC MYELOGENOUS LEUKEMIA (CML) PATIENTS, A
PROJECT TOWARDS EXPANDING AN AUTOGRAFT FOR TRANSPLANTATION
256. CO-EXPRESSION OF P190 AND P210 TRANSCRIPT IN A PEDIATRIC CHRONIC MYELOID
LEUKEMIA PATIENT AT THE TIME OF BLAST CRISIS
257. ASSESMENT OF THE EFFICACY OF HESA-A ON THE PROLIFERATION AND APOPTOSIS OF
CHRONIC MYELOGENOUS LEUKEMIA CELL LINE
258. SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS.
259. SUCCESSFUL MANAGEMENT OF CML DURING PREGNANCY AND IN POST-PARTUM PERIOD
260. BCR-ABL TRANSCRIPT LEVELS AT 3 AND AT 6 MONTHS ARE PREDICTIVE FOR SURVIVAL, TIME
TO TRANSFORMATION AND TIME TO SECOND LINE TREATMENT ONSET IN CHRONIC MYELOID LEUKEMIA
PATIENTS ON IMATINIB THERAPY
261. APPLICATION OF THE EUTOS SCORE IN A SERIES OF PATIENTS WITH CHRONIC MYELOID
LEUKEMIA (CML) IN CHRONIC PHASE (CP) TREATED WITH TYROSIN KINASE INHIBITORS (TKI)
262. USING OF TYROSINE KINASE INHIBITORS IN FEMALES WITH CHRONIC MYELOD LEUKEMIA
DURING PREGNANCY AND CONSIDERATIONS FOR TRANSPLACENTAL PENETRARION OF LEUKEMIC CELLS
AND DRUGS
263. VALIDATION OF A PROGNOSTIC SCORING SYSTEM IN PATIENTS TREATED WITH SECONDGENERATION TYROSINE KINASE INHIBITORS FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
AFTER IMATINIB FAILURE
264. CARTRIDGE-BASED AUTOMATED METHOD FOR BCR-ABL QUANTIFICATION IN CHRONIC MYELOID
LEUKEMIA PATIENTS WITH COMPLETE MOLECULAR RESPONSE ON TYROSINE KINASE INHIBITORS
THERAPY
265. SKIN ADVERSE EFFECTS OF TYROSINE KINASE INHIBITORS IN THE THERAPY OF PATIENTS
WITH CHRONIC MYELOID LEUKEMIA – SINGLE CENTRE EXPERIENCE
266. CONTRIBUTION OF THE EPIDEMIOLOGICAL AND CLINICAL REGISTRIES TO XXI CENTURY
MEDICINE. RESULTS FROM THE ANDALUSIAN REGISTRY OF CHRONIC MYELOID LEUKEMIA (RALMC)
267. COST-EFFECTIVENESS ANALYSIS IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN
JAPAN
268. PREGNANCIES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYSOSINE
KINASE INHIBITORS
269. EARLY RESPONSE RATES TO THERAPY IN CHRONIC PHASE CML ARE HIGHER WITH NILOTINIB
COMPARED WITH IMATINIB FRONTLINE THERAPY AND ARE PREDICTED BY THE EUTOS SCORE
270. EXPRESSION OF DRUG TRANSPORTER GENES IN CHRONIC MYELOID LEUKEMIA WITH IMATINIB
RESISTANCE TREATED BY SECOND GENERATION TYROSINE KINASE INHIBITORS
271. THROMBOPOIETINE RECEPTOR AGONISTS ARE EFFECTIVE TO MANAGE THROMBOCYTOPENIA ON
TKI-TREATMENT
272. SCREENING OF ABL KINASE DOMAIN MUTATIONS USING NEXT GENERATION SEQUENCING IN
CHRONIC MYELOID LEUKAEMIA: IMPACT IN THE RESPONSE TO TREATMENT WITH TYROSINE KINASE
INHIBITORS
273. NEUROMUSCULAR TOXICITY OF TYROSINE KINASE INHIBITORS IN THE THERAPY OF PATIENTS
WITH CHRONIC MYELOID LEUKEMIA
274. COMPARISON OF BCR-ABL1 GENE EXPRESSION ASSESSED BY GENEXPERT V1 AND V1-IMPROVED
CARTRIDGES VERSUS ELN STANDARDIZED RQ-PCR METHOD IN PATIENTS WITH CHRONIC MYELOID
LEUKEMIA TREATED WITH TKIS
275. HEALTH-RELATED PROFILES INCLUDING QUALITY OF LIFE AFTER CESSATION OF IMATINIB IN
CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH UNDETECTABLE MOLECULAR RESIDUAL
DISEASE
276. IDENTIFICATION AND CHARACTERISTICS OF CANDIDATES FOR CESSATION OF TYROSINE
KINASE INHIBITORS AMONG PATIENTS WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
SHOWING DURABLE COMPLETE MOLECULAR RESPONSE
277. EVALUATION OF SECOND-GENERATION TYROSINE KINASE INHIBITORS EFFICACY AND SAFETY
IN NOVO CML-CP THERAPY. RESULTS OF 29 PATIENTS OUTSIDE OF CLINICAL TRIALS FROM THE
CML ANDALUSIAN GROUP
278. TYROSINE KINASE DOMAIN MUTATIONS AND CYP3A4-CYP3A5 GENE POLYMORPHISMS IN
IMATINIB RESISTANT CHRONIC MYELOID LEUKEMIA
279. APPLICATION OF D-FISH ON BONE MARROW AND PERIPHERAL BLOOD SAMPLES FOR THE
EVALUATION OF CYTOGENETIC RESPONSE TO TKIS THERAPY IN CHRONIC MYELOID LEUKEMIA
280. SIGNIFICANCE OF EUTOS AND HAMMERSMITH SCORE IN SECOND LINE TYROSINE KINASE
INHIBITORS
281. BENEFITS/RISKS OF DASATINIB THERAPY IN PATIENTS WITH IMATINIB-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA: PHYSICIAN’S AND PATIENT’S PERSPECTIVE
282. STRUCTURE OF MORTALITY DURING INTERNATIONAL RESEARCH PROJECT THE EUROPEAN
OUTCOME AND TREATMENT STUDY FOR CML, OUT STUDY PATIENTS (EUTOS OSP) IN RUSSIA OF
PATIENTS WITH CHRONIC MYELOID LEUKEMIA
283. CO-EXPRESSION OF P190 AND P 210 BCR-ABL FUSION TRANSCRIPTS AND RESPONSE TO TKI
THERAPY IN CHRONIC MYELOID LEUKEMIA: THE RET (RETE EMATOLOGICA TOSCANA) EXPERIENCE
284. FREQUENCY OF HYPOCALCEMIA IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA RECEIVING
TYROSINE KINASE INHIBITOR THERAPY
285. EVALUATION OF TWO THERAPEUTIC STRATEGIES IN PATIENTS WITH CHRONIC MYELOID
LEUKAEMIA IN SUBOPTIMAL RESPONSE TO IMATINIB
286. EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA(CML) IN THE ERA OF TYROSINE
KINASE INHIBITORS (TKIS)
287. BLAST CRISIS OF CHRONIC MYELOID LEUKEMIA: LABORATORY, IMMUNOPHENOTYPC, AND
CYTOGENETIC HALLMARKS AND RESPONSE TO THERAPY
288. PROGNOSTIC VALUES EUTOS AND SOKAL SCORES IN NEWLY DIAGNOSED CML CP PATIENTS
289. IMATINIB THERAPY RESPONSE IN CML PATIENTS WITH DIFFERENT BCR/ABL P210
TRANSCRIPTS
290. A FRET-BASED DRUG SENSITIVITY TEST PREDICTS A CLINICAL OUTCOME OF CML PATIENTS
AT THE DIAGNOSIS
291. FOUR CASES OF CML BLAST PHASE AS INITIAL PRESENTATION DIAGNOSED BY FLUORESCENCE
IN SITU HYBRIDIZATION SHOWING BCR-ABL1 SIGNALS IN MATURE NEUTROPHILS
292. A POPULATION STUDY OF OUTCOMES IN CHRONIC MYELOID LEUKAEMIA IN N.IRELAND FROM
2000-PRESENT.
293. ASSOCIATION OF GENE HLA-DRB1 POLYMORPHISM WITH THE OUTCOME OF THERAPY OF CHRONIC
MYELOID LEUKEMIA WITH IMATINIB
294. ACCELERATED PHASE OF CHRONIC MYELOID LEUKEMIA: THE IMPACT OF THE DIFFERENT
CRITERIA ON TREATMENT RESPONSE AND SURVIVAL
295. COMPARISON OF THE SOKAL AND EUTOS PROGNOSTIC SCORES IN PATIENTS WITH CML: ONE
CENTER’S EXPERIENCE
296. DYNAMICS OF T315I MUTATION IN PHILADELPHIA POSITIVE PATIENTS ON TYROSINE KINASE
INHIBITOR THERAPY
297. LOSS OF PREVIOUS COMPLETE CYTOGENETIC RESPONSE AND ABRUPT BLAST TRANSFORMATION
DURING LONG TERM FOLLOW UP OF CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE
TREATED WITH IMATINIB
298. CYTOGENETIC AND MOLECULAR RESPONSE AT 3 MONTHS AFTER SECOND-TKI THERAPY AND
CORRELATION WITH LONG-TERM OUTCOMES FOR CML CHRONIC PHASE PATIENTS. EXPERIENCE IN ONE
CENTER
299. INCIDENTAL FINDING AND EVOLUTION OF PH+ CLONE IN TWO PATIENTS WITH
KIDNEY/PANCREAS TRANSPLANT AND DIFFUSE LARGE B-CELL LYMPHOMA
300. EXPRESSION PATTERN OF CANCER-TESTIS ANTIGENS SP17, GAGE1, HAGE, NY-ESO1, MAGE1,
PASD1, SCP, SEMG, SLLP1, SPANXA, SSX1 AND PRAME IN CML.
301. THE STUDY OF THE INFLUENCE OF PRIOR THERAPY ON RESPONSE TO TYROSINE KINASE
INHIBITORS THERAPY IN CML PATIENTS
302. FAST PROGRESS OF A CML PATIENT WITH UNUSUAL GENETIC ABNORMALITIES – A CASE STUDY
303. THE ALTERATION OF CPK IN CML PATIENTS TREATED WITH IMATINIB HAS IMPACT ON
RESPONSE AND TOXICITY?
304. CHRONIC MYELOID LEUKEMIA ASSOCIATED WITH OTHER HEMATOLOGIC AND NON-HEMATOLOGIC
MALINANCIES: REPORT OF FOUR CASES
305. LMO2 EXPRESSION DOES NOT EFFECT CYTOGENETIC AND MOLECULAR RESPONSE IN CML
PATIENTS TREATED WITH IMATINIB
306. EIGHT YEAR RESULTS OF THE THERAPY OF CML TYROSINE KINASE INHIBITOR IN A LARGE
INDUSTRIAL CENTER OF SIBERIA
307. DASATINIB IS EFFECTIVE IN ETV6-ABL1 CML LIKE DISORDER WITH COMPLEX TRANSLOCATION
INVOLVING CHROMOSOME 9, 12 AND 14
308. IMMUNOLOGICALLY
DETECTION OF BCR/ABL FUSION PROTEIN WITH FLOW CYTOMETRY IN
K562 CHRONIC MYELOID LEUKEMIA CELLS AND COMPARISON WITH RT-PCR RESULTS
309. COMPARISON OF FLUORESCENCE IN SITU HYBRIDIZATION AND CHROMOSOME BANDING ANALYSIS
FOR THE DEFINITION OF COMPLETE CYTOGENETIC RESPONSE IN CHRONIC MYELOID LEUKEMIA
PATIENTS TREATED WITH GLEEVEC.
310. B-CELL CLONES IN HODGKIN'S LYMPHOMA DETECTED BY NEW GENERATION SEQUENCING
311. IDO IS FREQUENTLY EXPRESSED IN STROMAL CELLS OF HODGKIN LYMPHOMA AND IS
ASSOCIATED WITH ADVERSE CLINICAL FEATURES
312. PROGNOSTIC SIGNIFICANCE OF CD68, CD20, FOXP3 EXPRESSION; PRESENCE OF EPSTEINBARR VIRUS AND MAST CELL INFILTRATION IN CLASSICAL HODGKIN LYMPHOMA PATIENTS
313. PROGNOSTIC IMPACT OF PERIPHERAL BLOOD LYMPHOCYTE IMMUNOPHENOTYPES IN CLASSICAL
HODGKIN’S LYMPHOMAS
314. PROCALCITONIN (PCT) LEVELS IN NEWLY DIAGNOSED PATIENTS WITH HODGKIN LYMPHOMA
(HL) PRESENTING WITH FEVER AND/OR ELEVATED C-REACTIVE PROTEIN (CRP)
315. CHEMOTHERAPY ALONE VERSUS CHEMOTHERAPY PLUS RADIOTHERAPY FOR ADVANCE STAGE
HODGKIN’S LYMPHOMA: A SYSTEMATIC REVIEW
316. SURVEILLANCE IMAGING OF HODGKIN’S LYMPHOMA – IS THERE ANY ADVANTAGE?
317. RESULTS OF ABVD AND BEACOPP CHEMOTHERAPY IN ADULT PATIENTS WITH EARLY STAGE
HODGKIN`S LYMPHOMA- A SINGLE CENTER RETROSPECTIVE STADY
318. BENDAMUSTINE-BASED THERAPY IS EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN
THE TREATMENT OF REFRACTORY AND RELAPSED HODGKIN LYMPHOMA.
319. RISK FACTORS IN AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA : A
SINGLE-CENTRE EXPERIENCE
320. BRENTUXIMAB VEDOTIN IS AN EFFECTIVE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA TYPE
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)
321. THE ROLE OF POSITRON EMISSION TOMOGRAPHY (PET) IMAGING IN THE TREATMENT
STRATIFICATION OF STAGE I-II HODGKIN LYMPHOMA
322. EVALUATION OF THE MANAGEMENT OF HODGKIN’S DISEASE IN BLIDA, ALGERIA
323. PROGNOSTIC VALUE OF 18F-FDG PET/CT IN HODGKIN LYMPHOMA
324. COMPARISON OF BONE MARROW INVOLVEMENT BY FDG PET/CT AND HISTOPATHOLOGY IN
PATIENTS WITH LYMPHOMA
325. OUTCOME OF HIGH RISK HODGKIN'S LYMPHOMA IN THE SOUTH-EST OF ALGERIA.
326. ANALYSIS AND VALIDATION OF THE MIRNA EXPRESSION PROFILE IN PLASMA FROM PATIENTS
DIAGNOSED WITH MYELODYSPLASTIC SYNDROME
327. PROGNOSTIC SIGNIFICANCE OF GATA-1 AND WT1 LEVELS IN PEDIATRIC HEMATOLOGICAL
DISORDERS
328. ANALYSIS OF BONE MARROW CD34(+) SUBPOPULATIONS BY FLOW CYTOMETRY IN PATIENTS
WITH MYELODYSPLASTIC SYNDROMES
329. COMPOSITION OF BONE MARROW SUBPOPULATIONS ANALYZED BY FLOW CYTOMETRY REVEALS
DIFFERENCES BETWEEN PEDIATRIC APLASTIC ANEMIA AND REFRACTORY CYTOPENIA
330. PERFORMANCE CHARACTERISTICS OF CONSENSUAL APPROACHES FOR SMALL AND MINOR
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONE DETERMINATION BY FLOW CYTOMETRY
331. DIAGNOSIS AND MONITORING OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA BY
MULTIPARAMETER FLOW CYTOMETRY. OPTIMIZATION OF PROTOCOLS BASED ON CD59, CD55 AND
FLAER
332. ASSESSMENT OF RESPONSE TO RECOMBINANT ERYTHROPOIETIN IN LOW GRADE
MYELODYSPLASTIC SYNDROME
333. ANALYSIS OF VB T CELL REPERTOIRE IN MDS PATIENTS
334. PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA CLONE IN APLASTIC ANAEMIA PATIENTS AT THE
BEGINNING OF DISEASE AND IN REMISSION.
335. APPLICATION OF INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION IN MYELODYSPLASTIC
SYNDROMES AND THE ASSOCIATION WITH CLINICAL FEATURES
336. A PHASE 4, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS (PK) OF
SUBCUTANEOUS (SC) AZACITIDINE IN TAIWANESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC
SYNDROMES (MDS)
337. CIRCULATING FETUIN-A/?2HS-GLYCOPROTEIN LEVELS IN MYELODYSPLASTIC SYNDROME
338. STRIKING HEMATOLOGICAL ABNORMALITIES IN PATIENTS WITH MICROCEPHALIC
OSTEODYSPLASTIC PRIMORDIAL DWARFISM TYPE II MAY INDICATE A POTENTIAL ROLE OF
PERICENTRIN GENE IN HEMATOPOIESIS
339. CASE SERIES OF APLASTIC ANEMIA; AN INSTITUTION BASED REVIEW
340. POSITIVE OUTCOMES OF THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH
ECULIZUMAB THERAPY
341. DETECTION OF PNH-CLONE IN PATIENTS WITH DEPRESSION OF HEMOPOIESIS
342. LENALIDOMIDE (LEN) IN MYELODYSPLASTIC (MDS) DEL(5Q) PATIENTS: A SINGLE
INSTITUTION POPULATION-BASED EXPERIENCE
343. MORPHOLOGICAL FEATURES OF HEMATOPOIESIS IN MDS PATIENTS UNDERGOING ALLOGENEIC
STEM CELL TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING
344. AZACYTIDINE THERAPY FOR MDS AND AML PATIENTS: RETROSPECTIVE MULTICENTRE REGIONAL
EXPERIENCE IN PATIENTS NOT ENROLLED INTO CLINICAL TRIALS.
345. CLINICAL FEATURES AND ANALYSIS OF PROGNOSTIC RISK FACTORS OF 124 PATIENTS WITH
MYELODYSPLASTIC SYNDROME
346. OVERVIEW OF RUSSIAN PNH REGISTRY
347. ACQUIRED APLASTIC ANEMIA : DIAGNOSTIC AND THERAPEUTIC ASPECTS
348. COMBINED OVEREXPRESSION OF WT1 AND BAALC GENES MAY PREDICT AML EVOLUTION IN MDS
PATIENTS
349. RABBIT ANTITHYMOCYTE GLOBULIN IN CHILDHOOD ACQUIRED SEVERE APLASTIC ANEMIA
350. PROGNOSTIC MARKERS FOR MYELODYSPLASTIC SYNDROME
351. MONITORING OF THE CYTOGENETIC ALTERATIONS IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA/MYELODYSPLASTIC SYNDROME TREATED WITH AZACITIDINE
352. SMALL IMPACT OF NEW CYTOGENETIC SCORE SYSTEM FOR MYELODISPLASTIC SYNDROMES ON
CLINICAL PRACTICE
353. COMBINED USE OF AZACITIDINE (AZA) & RECOMBINANT HUMAN ERYTHROPOIETIN (RHUEPO)
INDUCES RAPID HAEMATOLOGICAL RESPONSE WITHOUT AFFECTING RESPONSE RATE IN HIGHER RISK
MDS: RESULTS OF A RETROSPECTIVE STUDY
354. AZACITIDINE: AN ALTERNATIVE TREATMENT REGIMEN FOR ELDERLY HIGH-RISK
MYELODYSPLASTIC PATIENTS
355. COMPARATIVE EFFICACY OF HOMOHARRINGTONINE PLUS CYTARABINE AND DECITABINE IN
PATIENTS WITH MDS/AML
356. LIPOSOMAL IRON IS BETTER THAN IRON SULFATE IN LOW-RISK MYELODYSPLASTIC SYNDROMES
(LR-MDS) WITH MILD ANEMIA. MONOCERNTRIC STUDY.
357. EXPERIENCE WITH 5-AZACYTIDINE IN EAST KENT: WHEN TO QUIT?
358. LENALIDOMIDE TREATMENT IN 20 PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS).
MULTICENTER REGISTRY
359. RESPONSE TO ECULIZUMAB COMBINED WITH CYCLOSPORINE AFTER FAILURE OF ECULIZUMAB
MONOTHERAPY IN 2 PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
360. EFFICACY OF ERYTHROPOIESIS-STIMULATING AGENTS IN ANEMIC PATIENTS WITH
MYELODYSPLASTIC SYNDROME
361. DELETION 5Q MYELODYSPLASTIC SYNDROMES (MDS) TREATMENT AND DIAGNOSTIC PATTERNS IN
MEXICO: RESULTS FROM A PHYSICIAN SURVEY
362. A RETROSPECTIVE REVIEW OF THE TREATMENT OF APLASTIC ANEMIA
363. LONG TERM AZACYTIDINE THERAPY IN RESPONDING MDS IS FEASIBLE AND PROLONGS
THEAREPEUTIC BENEFIT: ANALYSIS IN 18 ELDERLY PATIENTS
364. EVALUATION OF FLOW CYTOMETRIC SCORE FOR THE DIAGNOSIS OF LOW-GRADE
MYELODYSPLASTIC SYNDROMES
365. A NEW CASE OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS AND THROMBOCYTOSIS SF3B1
AND JAK2 V617F POSITIVE, RESPONDING TO LENALIDOMIDE MONOTHERAPY.
366. OUTCOME OF 5-AZACITIDINE AND DECITABINE TREATMENT IN ELDERLY PATIENTS WITH
MYELODYSPLASTIC SYNDROME
367. MELATHONIN PLUS DANAZOLE, PREDNISONE AND ERYTHROPOIETIN ALPHA IS EFFECTIVE IN
TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH ANEMIA AND THROMBOCYTOPENIA.
368. CLINICAL ANALYSIS OF 24 PATIENTS WITH SEVERE APLASTIC ANEMIA AND VERY SEVERE
APLASTIC ANEMIA TREATED WITH ANTITHYMOCYTE GLOBULIN(ATG) COMBINED WITH CYCLOSPORINE
369. EFFICACY AND TOLERABLITY OF AZACITIDINE TREATMENT IN PATIENTS WITH MDS, AML AND
CMML
370. INTESTINAL ANGIODYSPLASIAS AND MYELOSYPPRESSION: 3 CASE REPORTS- THE ROLE OF
LONG ACTING OCTREOTIDE
371. CLINICAL TRIAL OF PROPHYLACTIC ANTIFUNGAL AND ANTIVIRAL THERAPY IN SAA/VSAA
PATIENTS UNDERGOING IMMUNOSUPPRESSIVE THERAPY
372. SUCCESSFULL AZACITIDINE BASED TREATMENT OF THERAPY RELATED MYELODYSPLASTIC
SYNDROME WITH NORMAL KARYOTYPE OCCURRED AFTER ACUTE MYELOID LEUKEMIA
373. RAPID HAEMATOLOGICAL RESPONSE WITH 5-AZACYTIDINE IN HIGH RISK MYELODYSPLASTIC
SYNDROME
374. A RARE DISEASE IN CHILDHOOD: PNH AND ITS TREATMENT WITH ECULIZUMAB
375. THE NOVEL PAN-HDAC INHIBITOR, CKD-581 ENHANCES THE ANTI-MYELOMA EFFECTS OF
BORTEZOMIB
376. IMMUNOPHENOTYPIC ANALYSIS OF BONE MARROW B LYMPHOCYTE PRECURSORS (HEMATOGONES)
IN PLASMA CELL DISORDERS: A NEW MARKER OF DISEASE?
377. POTENTIAL ROLE OF PPAR-G AND HMOX1 IN MULTIPLE MYELOMA (MM) CELL DEATH
378. INFLAMMATORY MONOCYTES ARE INCREASED IN MM AND CORRELATED TO EXTENSION OF BONE
DISEASE
379. INCREASED SERUM LEVELS OF MIP-1ALPHA CORRELATE WITH BONE DISEASE AND ANGIOGENIC
CYTOKINES IN MULTIPLE MYELOMA PATIENTS
380. EPILEPSY DOSES OF VALPROATE COMBINED WITH THE ANTI-HELMINTHIC, NICLOSAMIDE,
SYNERGISTICALLY KILL MYELOMA CELLS: A POTENT NEW ANTI-MYELOMA DRUG COMBINATION.
381. TRANSLOCATION T(14;16): FREQUENCY AND SIGNIFICANCE IN PATIENTS WITH MULTIPLE
MYELOMA
382. THE RELATIONSHIP OF MYELOMA CELLS, STROMAL CELLS AND MONOCYTES UNDER BONE MARROW
MICROENVIRONMENT
383. BORTEZOMIB UPREGULATES OSTERIX AND OSTEOCALCIN IN OSTEOBLASTS AND REDUCED
MYELOMA-INDUCED APOPTOSIS
384. ANALYSIS OF B-CELLS AND PLASMA CELLS IN MONOCLONAL GAMMOPATHIES
385. SPHINGOSINE KINASE 2 IS OVEREXPRESSED IN PATIENTS AFFECTED BY MULTIPLE MYELOMA
386. ESTABLISHMENT OF A BORTEZOMIB-RESISTANT CELL LINE KM3/BTZ
387. IMPACT OF P53 PERCENTAGE IN SURVIVAL OF PATIENTS DIAGNOSED OF MULTIPLE MYELOMA
388. CYTOTOXIC EFFECTS OF APIGENIN ON MULTIPLE MYELOMA CELLS
389. TREND ANALYSIS OF P53 AND AMPLIFICATION OF CYCLIN D1 GENE IN MULTIPLE MYELOMA
AFTER BORTEZOMIB AND DOUBLE AUTOLOGOUS STEM CELL TRANSPLANTATION
390. PROGNOSTIC VALUE OF 13Q14 DELETION AND IGH REARRANGEMENT BY INTERPHASE FISH IN
EGYPTIAN MULTIPLE MYELOMA PATIENTS
391. ROLE OF 18 F-FDG PET/CT IN THE ASSESSMENT OF PATIENTS WITH SMOLDERING MULTIPLE
MYELOMA
392. INVESTIGATION OF THE RELATIONSHIP BETWEEN TREATMENT EFFECTS ON PROGRESSION FREE
SURVIVAL AND OVERALL SURVIVAL IN CLINICAL TRIALS OF MULTIPLE MYELOMA BASED ON
PUBLISHED LITERATURE
393. C-MYC GENE RELATED ABNORMALITY AND ADDITIONAL CHROMOSOME 8 WERE UNIQUE
CYTOGENETIC ABERRATION IN MULTIPLE MYELOMA
394. PLASMA CELL PROLIFERATION FRACTION AND THE RISK OF PROGRESSION FROM SMOLDERING
MULTIPLE MYELOMA (SMM) TO MULTIPLE MYELOMA (MM)
395. DOMESTIC SUBCUTANEOUS SELF-INJECTION OF BORTEZOMIB IN MULTIPLE MYELOMA
396. BORTEZOMIB (BTZ) RETREATMENT FOR RELAPSED/REFRACTORY (REL/REF) MULTIPLE MYELOMA
(MM) IN REAL-WORLD MEDICAL PRACTICE: FINAL DATA FROM THE INTERNATIONAL, NONINTERVENTIONAL, OBSERVATIONAL EVOBS STUDY
397. ELIMINATING THE NEED FOR 24-HOUR URINE STUDIES IN PHASE I MYELOMA PATIENTS
398. CONTRIBUTION OF DIFFUSION AND ADC SEQUENCES IN WHOLE BODY MRI FOR MYELOMA
STAGING
399. SUBCUTANEOUS ADMINISTRATION OF BORTEZOMIB REDUCES ADVERSE EVENTS
400. COMORBIDITY IMPACT SURVIVAL IN MULTIPLE MYELOMA. A SINGLE INSTITUTION STUDY
DEALING WITH VALIDATION OF ACE-27 SCORE
401. EXPLORATION AND QUANTIFICATION OF THE DETERMINANTS OF BASELINE HEALTH-RELATED
QUALITY OF LIFE (HRQOL) FOR PATIENTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
402. ALLOGENEIC STEM-CELL TRANSPLANTATION IN MULTIPLE MYELOMA IN REAL PRACTICE:
LONG-TERM RESULTS FROM A SINGLE INSTITUTION.
403. BORTEZOMIB-BASED THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REALWORLD MEDICAL PRACTICE: FINAL DATA FROM THE INTERNATIONAL, OBSERVATIONAL EVOBS STUDY
404. ISOTYPE MATCHED IMMUNOGLOBULIN RECOVERY RATES IN IGG AND IGA MYELOMA PATIENTS AT
MAXIMUM RESPONSE SUGGEST SUBTLE ISOTYPE SPECIFIC DIFFERENCES IN IMMUNE-RECONSTITUTION
405. DESCRIPTIVE STUDY CASES OF AMYLOIDOSIS: SUBANALYSIS OF CARDIAC INVOLVEMENT
406. THE IDEAL DOSE SETTING AND THE POSSIBILITY OF THERAPEUTIC DRUG MANAGEMENT OF
LENALIDOMIDE ACCORDING TO PLASMA CONCENTRATION IN MULTIPLE MYELOMA
407. RENAL FAILURE IS REVERSIBLE AFTER THERAPY WITH BORTEZOMIB IN PATIENTS WITH
MULTIPLE MYELOMA
408. PROGNOSTIC VALUE OF IGM HEAVY IMMUNOGLOBULINS CHAIN ANALYSIS IN IGM MGUS AND
WALDENSTRÖM MACROGLOBULINEMIA
409. LENALIDOMIDE 25 MG + LOW-DOSE DEXAMETHASONE: EFFICACY & SAFETY IN CHINESE
PATIENTS WITH RELAPSED/REFRACTORY MYELOMA
410. EFFICACY AND SAFETY OF PERCUTANEOUS VERTEBROPLASTY IN PATIENTS WITH SPINAL
MYELOMA LESIONS.
411. “REAL WORLD” DATA FROM PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO
HAVE BEEN TREATED WITH LENALIDOMIDE AND DEXAMETHASONE, ACCORDING TO THE STANDARD
CLINICAL PRACTICE
412. BORTEZOMIB, NON-PEGYLATED LIPOSOMAL DOXORUBICIN, DEXAMETHASONE (PAD) REGIMEN AND
AUTOLOGOUS STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA: PRELIMINARY
RESULTS OF A PILOT STUDY
413. LIMITED SURVIVAL FOLLOWING SEQUENTIAL EXPOSURE TO CURRENTLY AVAILABLE NOVEL
AGENTS IN MULTIPLE MYELOMA (MM): THE CASE FOR NEW THERAPEUTIC STRATEGIES
414. ADDING CYCLOPHOSPHAMIDE TO LENALIDOMIDE-DEXAMETHASONE – A SAFE STATEGY TO
IMPROVE RESPONSE IN RELAPSE/REFRACTORY MULTIPLE MYELOMA
415. EVALUATION OF CD 45 EXPRESSION ON PATIENTS WITH MULTIPLE MYELOMA AND ITS EFFECT
ON THE TIME TO PROGRESSION
416. FREQUENCY DYNAMICS AND PROGNOSTIC IMPACT OF WEIGHT LOSS AND BODY MASS INDEX IN
MULTIPLE MYELOMA AT DIAGNOSIS
417. PREDICTIVE VALUE OF LIGHT AND HEAVY CHAIN ANALYSIS IN MULTIPLE MYELOMA
PATIENTS TREATED WITH BORTEZOMIB
418. LENALIDOMIDE/DEXAMETHASONE (RD) IN REFRACTORY/RELAPSED MULTIPLE MYELOMA: A
RETROSPECTIVE MULTI-CENTER STUDY FROM “RETE EMATOLOGICA PUGLIESE” (REP).
419. IMMUNOPHENOTYPIC ASSESSMENT AND CLINICAL OUTCOME IN PATIENTS AFFECTED BY
MULTIPLE MYELOMA (MM)
420. LONG-TERM USE OF LENALIDOMIDE IN PATIENTS WITH RELAPSED MYELOMA IN A SINGLE
CENTRE: RESPONSE, TOXICITY AND FACTORS AFFECTING SURVIVAL.
421. THE CHOICE OF REGIMENS BASED OF BORTEZOMIB FOR PATIENTS WITH NEWLY DIAGNOSED
MULTIPLE MYELOMA: EXPERIENCES FROM CHINA
422. THERAPEUTIC RESPONSE IN PATIENTS WITH MACROFOCAL FORM OF MULTUPLE MYELOMA ,
TREATED WITH BORTEZOMIB - CONTAINING REGIMENS
423. LENALIDOMIDE CONSOLIDATION THERAPY FOLLOWED BY LENALIDOMIDE MAINTENANCE AFTER
FIRST LINE THERAPY FOR MULTIPLE MYELOMA
424. SECOND AUTOLOGOUS TRANSPLANTATION FOR PATIENTS WITH RELAPSED MULTIPLE MYELOMA
425. EARLY ACHIEVEMENT OF A GOOD QUALITY RESPONSE PREDICTS BETTER OUTCOME IN MULTIPLE
MYELOMA
426. EFFICACY OF LONG-TERM LENALIDOMIDE TREATMENT OF MM PATIENTS WITH AT LEAST ONE
PRIOR THERAPY BASED ON CZECH LOCAL DATA
427. MATHEMATICAL MODEL OF SERUM FREE LIGHT CHAIN DECLINE IDENTIFIES A KINETIC
PREDICTIVE MARKER OF SURVIVAL IN PATIENTS WITH MYELOMA TREATED WITH BORTEZOMIB,
DEXAMETHASONE AND STEM CELL TRANSPLANTATION
428. STUDY OF THE PROGNOSTIC VALUE OF SERUM FREE LIGHT CHAINS RATIO AT DIAGNOSIS IN
SPANISH POPULATION WITH MULTIPLE MYELOMA
429. DIFFERENCES AMONG MGUS AND MGUS WITH ASSOCIATED DISEASES AT DIAGNOSIS AND FOLLOW
UP
430. FAMILIAL MULTIPLE MYELOMA
431. HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE
MYELOMA. A SINGLE CENTER EXPERIENCE FROM EHU1ST NOVEMBER OF ORAN.
432. PREVALENCE OF OLIGOSECRETARY MYELOMA AND ITS CLINICAL IMPLICATION: AN ASIAN
SINGLE-CENTER EXPERIENCE
433. THE CONTRIBUTION OF SERUM FREE LIGHT CHAINS ASSAY TO THE DIAGNOSIS AND FOLLOW UP OF PATIENTS WITH MULTIPLE MTELOMA- CLINICAL AND LABORATORY CORRELATION (A SINGLE
MEDICAL CENTER EXPERIENCE
434. MULTIPLE MYELOMA: A TEN YEAR EXPERIENCE OF A CENTRAL HOSPITAL
435. HEMOSTASIS IN PATIENTS WITH MULTIPLE MYELOMA BEFORE AND DURING HIGH-DOSE
CHEMOTHERAPY.
436. BENDAMUSTINE : A NEW OPTION FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
437. TWENTY-FIVE MG LENALIDOMIDE EVERY OTHER DAY IN PATIENTS AFFECTED BY MULTIPLE
MYELOMA AND RENAL FAILURE
438. SERUM FREE LIGHT CHAIN QUANTIFICATION IN MONOCLONAL GAMMOPATHIES AND MULTIPLE
MYELOMA PATIENTS
439. THE PREVALENCE OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) AND
ASYMPTOMATIC MULTIPLE MYELOMA (AMM) FOR HIGH RISK GROUPS
440. EPIDEMIOLOGICAL DATA OF MULTIPLE MYELOMA IN ALBANIA
441. A NEW OPPORTUNITY IN RELAPLSED AND REFRACTORY MULTIPLE MYELOMA : PEGYLATED
LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CED)
442. TREATMENT RESPONSE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
443. SIX YEAR RESULTS OF THE THERAPY OF MULTIPLE MYELOMA INTRACELLULAR PROTEASOME
INHIBITOR
444. LENALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN RELAPSE/REFRACTORY
MULTIPLE MYELOMA: A RETROSPECTIVE STUDY
445. TREATMENT OF BENCE-JONES MULTIPLE MYELOMA WITH CHEMOTHERAPY WITH/WITHOUT STEM
CELL TRANSPLANTATION446. A DATA INTEGRATION STRATEGY FOR HIGH-THROUGHPUT OMICS ANALYSES ALLOWS THE
PREDICTION OF NOVEL TRANSCRIPTION FACTOR TARGET GENES
447. PROANGIOGENETIC MOLECULES VEGF, HIF-1ALPHA AND ENOS IN MYELOPROLIFERATIVE
NEOPLASMS
448. EXPRESSION ANALYSIS OF JAK-STAT DEPENDENT S100 CALCIUM BINDING PROTEINS A4 AND
A12 IN MYELOPROLIFERATIVE NEOPLASMS
449. MICRORNA EXPRESSION ANALYSIS IN PATIENTS WITH PRIMARY MYELOFIBROSIS,
POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTOSIS
450. APOPTOSIS-RELATED GENES METHYLATION PROFILE IS ALTERED IN MYELOPROLIFERATIVE
NEOPLASMS PHILADELPHIA NEGATIVE PATIENTS
451. HUMAN PLATELET LYSATE AS A POTENTIAL SUBSTRATE FOR STUDYING MECHANISMS OF
MYELOFIBROSIS DEVELOPMENT
452. JAK2 46/1 HAPLOTYPE, JAK2V617F MUTATION AND CLINICAL CARACERISTICS OF THE
MACEDONIAN PATIENTS WITH CLASSICAL MYELOPROLIFERATIVE NEOPLASMS
453. GENETIC ABNORMALITIES IN DIAGNOSTICS OF BCR-ABL-NEGATIVE MYELOPROLIFERATIVE
NEOPLASMS
454. RECURRENT CEP85L-PDGFRB FUSION IN A PATIENT WITH A TRANSLOCATION T(5;6) AND AN
IMATINIB-RESPONSIVE MYELOPROLIFERATIVE NEOPLASM WITH EOSINOPHILIA
455. CLINICAL SIGNIFICANCE OF IMMATURE PLATELET FRACTION IN BCR-ABL1-NEGATIVE CHRONIC
MYELOPROLIFERATIVE NEOPLASMS
456. DISEASE CHARACTERISTICS AND PERIPHERAL BLOOD CD34+ CELLS IN IDIOPATHIC
MYELOFIBROSIS
457. THROMBOTIC CEREBRAL EVENTS IN ESSENTIAL THROMBOCYTHEMIA
458. CHARACTERIZATION OF DIFFERENT REGIMENS FOR INTRODUCING SECOND-LINE ANAGRELIDE:
RESULTS FROM A MULTICENTER STUDY OF 177 PATIENTS IN FRANCE
459. RISK OF LIMPHOPROLIFERATIVE NEOPLASMS IN PATIENTS WITH CHRONIC
MYELOPROLIFERATIVE NEOPLASMS
460. SERIAL ANALYSIS OF GENOMIC ABERRATIONS IN DIFFERENT PHASE OF PATIENTS WITH
MYELOPROLIFERATIVE AND MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS
461. GENETIC ABNORMALITIES ASSOCIATED WITH THROMBOSIS IN PATIENTS WITH PH-NEGATIVE
CHRONIC MYELOPROLIFERATIVE NEOPLASMS
462. HEMOGLOBINOPATHIA YPSILANTI – A RARE, BUT IMPORTANT DIFFERENTIAL DIAGNOSIS TO
POLYCYTHEMIA VERA
463. THE PREVALENCE OF LEG ULCERS IN PATIENTS WITH MYELOPROLIFERATIVE DISORDERS
TREATED WITH HYDROXYUREA
464. THE ROLE OF HISTOLOGICAL FEATURES IN PATIENTS WITH POLICYTHAEMIA VERA
465. COMPARISON OF THE EXPRESSION CANCER-TESTES (CT) ANTIGEN PROFILES IN CML AND
POLYCYTHEMIA VERA (PV).
466. EFFICACY OF PEGYLATED INTERFERON IN MYELO-PROLIFERATIVE DISORDERS
467. HYPEREOSINOPHILIC SYNDROME: DIAGNOSTICS AND THERAPY. SINGLE CENTRE EXPERIENCE
468. USING MYELOPROLIFERATIVE NEOPLASM SYMPTOM ASSESSMENT FORM (MPN-SAF) TO EVALUATE
QUALITY OF LIFE FOR PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA IN QATAR
469. PREGNANCY MANAGEMENT AND OUTCOMES IN WOMEN WITH MYELOPROLIFERATIVE DISEASES
470. COMMON COMMUNITY INFECTIONS AND THEIR ASSOCIATION WITH MYELOID MALIGNANCIES
471. INTERLEUKIN-8 LEVELS IN ESSENTIAL THROMBOCYTHEMIA: CLONAL OR INFLAMMATORY
TRIGGER?
472. PRIMARY MYELOFIBROSIS – A SURVEY BASED ON THE 20-YEARS’ EXPERIENCE OF A SINGLE
CENTER
473. 100 MG WEEKLY IMATINIB MAINTENANCE THERAPY IS SUFFICIENT TO SUSTAIN THE
MOLECULAR RESPONSE IN PATIENTS WITH CHRONIC EOSINOPHILIC LEUKEMIA
474. A RETROSPECTIVE ANALYSIS ON THE IMPACT OF PROGNSOTIC FACTORS IN 362 PATIENTS
WITH PRIMARY MYELOFIBROSIS FOLLOWED IN THE LAZIO REGION DURING A 20 YEARS FOLLOW-UP
PERIOD
475. THE ASSOCIATION BETWEEN JAK2 46/1 HAPLOTYPE AND SUSCEPTIBILITY TO
MYELOPROLIFERATIVE NEOPLASMS
476. PHILADELPHIA CHROMOSOME - NEGATIVE MYELOPROLIFERATIVE DISEASES AND
GASTROINTESTINAL BLEEDINGS
477. USE OF RADIO-ACTIVE PHOSPHORUS (P 32) IN THE MANAGEMENT OF POLYCYTHAEMIA RUBRA
VERA (PRV) AND PRIMARY THROMBOCYTHAEMIA (ET) IN EAST KENT UNIVERSITY HOSPITALS NHS
TRUST (EKUFHT) UK (01/01/2008 – 31/12/
478. 2 CASES OF IDIOPATHIC HYPEREOSINOPHILIC SYNDROME: A RARE DISORDER WITH SEVERE
THROMBOHAEMORRHAGIC COMPLICATIONS
479. SINGLE-AGENT LENALIDOMIDE IS EFFECTIVE FOR TRANSFUSION INDIPENDENCE IN A PATIENT
WITH REFRACTORY ANEMIA WITH RING SIDEROBLASTS, THROMBOCYTOSIS AND JAK2 (V617F)
480. CANINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AS A SPONTANEOUS ANIMAL MODEL OF
NON-GERMINAL CENTER DLBCL FOR PRECLINICAL STUDIES
481. EXPRESSION OF MIRNA-1234 RELATED STAT3 IN PATIENTS WITH DIFFUSE LARGE B-CELL
LYMPHOMA (DLBCL) FROM HIGH AND LOW INFECTIOUS DISEASE AREAS
482. SHRNA AGAINST CD44 EFFECT DIFFUSE LARGE B CELL LYMPHOMA CELLS
483. SEVEN MICRORNAS DIFFERENTIATE PATIENTS WITH EBV-POSITIVE DIFFUSE LARGE B-CELL
LYMPHOMA OF THE ELDERLY FROM DIFFUSE LARGE B-CELL LYMPHOMA NOT OTHERWISE SPECIFIED: A
MICRORNA SIGNATURE PROFILE PROPOSAL
484. SYNERGISTIC CYTOTOXICITY OF EDELFOSINE, GEMCITABINE AND CLOFARABINE IN T-CELL
LYMPHOMA
485. MOLECULAR AND IMMUNOHISTOCHEMICAL ANALYSIS OF CELL CYCLE REGULATORY GENES IN
DIFFUSE LARGE B-CELL LYMPHOMAS
486. CYTOGENETIC CHANGES AND HISTOLOGIC ASSESSMENT OF BONE MARROW INVOLVEMENT OF NK/T
CELL LYMPHOMA IN KOREAN
487. FREQUENT LOSS OF THE TUMOR SUPPRESSOR TNFAIP3 IN SÉZARY SYNDROME
488. GENETIC POLYMORPHISM OF GLUTATION-S-TRANSFERASES M1 AND T1 (GSTM1 AND GSTT1) AND
ENZYMES OF FOLATE METABOLISM IN THE PATIENTS WITH NON-HODGKIN MALIGNANT LYMPHOMAS
489. GERMINAL CENTER LYMPHOMA CELL LINES: TOOLS FOR THE STUDY OF CLONAL EVOLUTION?
490. CHARACTERIZATION OF CD19+CD5+ NON-CLL LYMPHOPROLIFERATIVE DISORDERS WITH AND
WITHOUT T(11;14)
491. GLUTATHIONE S-TRANSFERASE GENOTYPES INFLUENCE PROGNOSIS OF DIFFUSE LARGE B-CELL
LYMPHOMA
492. PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B-CELL LYMPHOMA (PCNSDLBCL) HARBOR
FREQUENT BCL6 BUT NOT MYC OR BCL2 TRANSLOCATIONS, AND BELONG TO THE NON-GERMINAL
CENTER SUBTYPE (NON-GC)
493. GENETIC POLYMORPHISMS ARG399GLN IN DNA REPAIR GENE XRCC1 AND RISK OF HIGH-GRADE
NHL ENTITIES
494. CASTLEMAN’S DISEASE: IMMUNOHISTOCHEMICAL ASSESSMENT OF NEOANGIOGENESIS IN
POEMS-SYNDROME
495. G-CSF BIOSIMILAR (ZARZIO®) STEM CELL MOBILIZATION IN SIBLING HEALTTHY DONORS
496. CLINICAL AND LABORATORIAL CHARACTERISTICS PREMOBILIZATION, DURING THE HARVEST
AND IN RELATION WITH THE AUTOLOGOUS STEM CELL TRANSPLANTATION OF ALL PATIENTS
MOBILIZED USING PLERIXAFOR IN OUR CENTRE
497. CHOLESTEROL SYNTHESIS INHIBITION INDUCES LEUKEMIA-SPECIFIC CYTOPROTECTIVE
AUTOPHAGY VIA SUPPRESSION OF THE AKT/MTOR SIGNALING PATHWAY
498. RNA IN RETICULOCYTES IS NOT A WASTE BUT A FINAL MESSENGER TO BECOME RBCS
499. APOPTOSIS AND CXCR4 EXPRESSION IN CHILDHOOD LEUKEMIA AND SOLID TUMORS
500. ELEVATION OF CAMP LEVELS INHIBITS ARSENIC-INDUCED APOPTOSIS IN ACUTE
PROMYELOCYTIC LEUKEMIA CELLS
501. THE PROLIFERATION ARREST OF PRIMARY BONE MARROW TUMOR CELLS DURING CULTURE IS
PRECEDED BY DOWNREGULATION OF MKI67 AND NUMEROUS MITOTIC AND TRANSCRIPTIONAL GENES
502. SANGIVAMYCIN-INDUCED APOPTOTIC INDUCTION IN HL-60 CELL LINE
503. HIGH FREQUENCY OF NQO1 C609T VARIANT GERMLINE POLYMORPHISM IN MDS/AML WITH
TRISOMY 8
504. AN IMPROVED REAL-TIME QUANTATIVE PCR PROTOCOL FOR DETECTING VARIANT-TYPE PMLRARA FUSION TRANSCRIPTS
505. DELETION OF 14Q IN COHORT OF 560 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA
506. MOLECULAR CHARACTERIZATION AND PRENATAL DIAGNOSIS OF FAMILIAL HEMOPHAGOCYTIC
LYMOPHOHISTOCYTOSIS IN EGYPTIANS
507. ASSOCIATION OF GSTP1 POLYMORPHISM AND CHROMOSOME ABERRATIONS IN ACUTE MYELOID
LEUKEMIA
508. EXTERNAL QUALITY ASSESSMENT OF KIT D816V MUTATION TESTING IN MASTOCYTOSIS
509. SUBMICROSCOPIC DELETIONS OF 3’-CBFB GENE PORTIONS IN ACUTE MYELOID LEUKEMIA WITH
INV(16): A COMPREHENSIVE DIAGNOSTIC APPROACH USING HIGH RESOLUTION MICROARRAY AND
LONG DISTANCE-PCR
510. MOLECULAR FACTORS ASSOCIATED WITH BONE INVOLVEMENT IN GAUCHER PATIENTS
511. CLINICAL SIGNIFICANCE OF PREVIOUSLY CRYPTIC COPY NUMBER ALTERATIONS AND LOSS OF
HETEROZYGOSITY USING THE COMBINED ARRAY CGH AND SNP MICROARRAY ANALYSIS IN CHILDREN
WITH AML AND MDS
512. HYPOXIA INDUCIBLE GENES, ERYTHROPOIETIN AND VASCULAR ENDOTHELIAL GROWTH FACTOR
EXPRESSION IN RENAL CELL CARCINOMA
513. PRODUCTION OF PLASMID CONTROL REAGENTS FOR MOLECULAR MONITORING OF ATYPICAL BCRABL1 FUSIONS
514. COMPARISON OF CONVENTIONAL CYTOGENETICS, MULTIPLEX RT-PCR, NPM AND FLT3 MUTATION
FOR THE DETECTION OF GENETIC ABNORMALITIES IN ACUTE MYELOID LEUKEMIA
515. CLINICAL AND MOLECULAR FINDING IN MACEDONIAN FAMILY WITH NIJMEGEN BREAKAGE
SYNDROM
516. A MULTIPLEX REAL TIME QUANTITATIVE PCR METHOD TO DETECT THE CO-EXPRESSION OF WT1
AND MDR1 GENE EXPRESSION IN ACUTE LEUKEMIA PATIENTS
517. UNUSUAL CONSTITUTIONAL ANOMALY T(11;12;20) IN A CASE OF MULTIPLE MYELOMA
518. EPSTEIN-BARR VIRUS LATENT MEMBRANE PROTEIN 1 INCREASES DRUG-RESISTANCE THROUGH
ENHANCED PKD
519. TRIPTOLIDE, A CHINESE HERBAL EXTRACT, SENSITIZES RESISTANT LEUKEMIA CELL LINES
THROUGH DOWN-REGULATION OF HIF-1? AND NRF2
520. CHANGES IN GENE EXPRESSION PROFILES IN RESPONSE TO APIGENIN IN IMATINIB
SENSITIVE AND RESISTANT CHRONIC MYELOID LEUKEMIA CELLS
521. VARIATION IN LEVELS OF SERUM IMMUNOGLOBULINS AND ITS RELATIONSHIP WITH THE
DEVELOPMENT OF SERIOUS INFECTIONS IN PATIENTS TREATED WITH RITUXIMAB
522. EFFECTS OF APIGENIN ON IMATININ-SENSITIVE AND RESISTANT CHRONIC MYELOID LEUKEMIA
CELLS
523. A CLINICAL MICRODOSE STUDY WITH 14C-ELACYTARABINE IN HEALTHY MALE SUBJECTS TO
GENERATE MASS BALANCE DATA TO SUPPORT REGULATORY SUBMISSION: AN INNOVATIVE
MICROTRACER APPLICATION
524. ROLE OF VKORC1 AND CYP4502C9 POLYMORHISM IN RESISTANCE TO WARFARIN THERAPY AMONG
EGYPTIAN PATIENTS
525. EVALUATION OF CHEMICAL STABILITY OF ROMIPLOSTIM IN STERILE WATER
526. SIROLIMUS EFFICIENCIES ON PEDIATRIC HEMATOLOGY PATIENTS
527. ACCURACY OF PHARMACOGENETIC ALGORITHMS FOR THE PREDICTION OF ACENOCOUMAROL
STABLE DOSES IN ANDALUSIAN POPULATION
528. FC GAMMA RECEPTOR POLYMORPHISMS IN PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANAEMIA
529. MOLECULAR CHARACTERIZATION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD)
DEFICIENCY IN ABU DHABI DISTRICT, UNITED ARAB EMIRATES (UAE)
530. REGULATION OF HEPCIDIN TRANSCRIPTION BY K-7174
531. GIVINOSTAT INDUCED APOPTOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
532. 4SC-202: A NOVEL EPIGENETIC MODULATOR TO TARGET CANCER STEM CELLS
533. NECROX-7 AS A NOVEL HMGB1 BLOCKADE ATTENUATES GRAFT-VERSUS-HOST DISEASE BY
AUGMENTING REGULATORY T CELLS AND INHIBITING DEVELOPMENT OF TH17 CELLS
534. MK-2206 SENSITIZES ACUTE MYELOID LEUKEMIA CELLS TO CYTARABINE VIA APOPTOSIS
INDUCTION
535. TIME TO HEMATOLOGIC AND RENAL IMPROVEMENTS IN AHUS PATIENTS WITH PROGRESSING
THROMBOTIC MICROANGIOPATHY AFTER COMMENCEMENT AND DURING CONTINUATION OF ECULIZUMAB
FOR MORE THAN 2 YEARS
536. RHTRAIL AND SURVIVIN DOWNREGULATORS AS NEW THERAPEUTIC APPROACH IN ACUTE
LYMPHOBLASTIC LEUKEMIA
537. SCREENING AND DELINEATION OF MOLECULAR MECHANISMS OF ACTION OF NOVEL AGENTS FOR
THE TREATMENT OF ?-THALASSAEMIA
538. HISTORICAL EVIDENCE OF SYSTEMIC MULTIORGAN COMPLICATIONS IN ATYPICAL HEMOLYTIC
UREMIC SYNDROME (AHUS) PATIENTS BEFORE ECULIZUMAB THERAPY EITHER IN PROSPECTIVE
TRIALS OR IN REAL-WORLD USE
539. VISMODEGIB – AN HEDGEHOG PATHWAY INHIBITOR INDUCES CELL DEATH IN AN ALL CELL
LINE
540. SELECTIVE SMALL MOLECULE AXL INHIBITOR BGB324 FOR THE TREATMENT OF ACUTE MYELOID
LEUKEMIA
541. BICYCLIC DERIVATIVES OF LIDONOJIRIMYCIN AS PHARMACOLOGICAL CHAPERONES FOR
NEURONOPATHIC FORMS OF GAUCHER DISEASE
542. ORIDONIN UPREGULATES RETINOIC ACID RECEPTORS AND SHOWS SYNERGISTIC EFFECT WHEN
USED IN COMBINATION WITH ALL-TRANS RETINOIC ACID IN T(8:21) LEUKEMIA
543. ROLE OF LENALIDOMIDE IN MANAGEMENT OF MYELODYSPLASTIC SYNDROMES (MDS) WITH
DEL(5Q) ASSOCIATED WITH PURE RED CELL APLASIA (PRCA)
544. GLYCOENGINEERED ANTIBODIES MEDIATE SUPERIOR MONOCYTE/MACROPHAGE-MEDIATED
PHAGOCYTIC AND CYTOTOXIC ACTIVITY COMPARED TO PARENTAL ANTIBODIES
545. MONITORING OF T-LYMPHOCYTE SUBPOPULATIONS IN PERIPHERAL BLOOD OF PATIENTS WITH
ACUTE LEUKEMIA (AL) DURING DONOR LYMPHOCYTE INFUSION (DLI) AFTER ALLOGENEIC BONE
MARROW TRANSPLANTATION (ALLO-BMT)
546. ERYTHROPOIETIN LEVEL IN SICKLE CELL DISEASE PATIENTS NOT IN CRISIS
547. EFFECTS OF IRON POLYMALTOSE COMPLEX, FERROUS FUMARATE AND FERROUS SULFATE
THERAPIES IN ANEMIC PREGNANT RATS, THEIR FETUSES AND PLACENTAS
548. ROLE OF REGULATORY T CELLS IN BETA THALASSEMIA
549. ENDOTHELIAL DYSFUNCTION IN YOUNG TRANSFUSION DEPENDENT B-THALASSEMIA PATIENTS
550. PEROXIREDOXINS PLAY AN IMPORTANT ROLE IN THE SURVIVAL OF ERYTHROID CELLS IN BETA
THALASSEMIA AND SICKLE CELL DISEASE PATIENTS.
551. COMPARISON OF THE PHYSICO-CHEMICAL CHARACTERISTICS OF ORIGINATOR IRON
POLYMALTOSE COMPLEX AND FOUR IRON POLYMALTOSE COMPLEX SIMILARS
552. BCL11A POLYMORPHIC VARIATIONS INFLUENCES FETAL HEMOGLOBIN LEVELS IN PORTUGUESE
SUBJECTS WITH COMMON HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN
553. NGAL (NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN): A NEW BIOMARKER FOR THE
DIFFERENTIAL DIAGNOSIS OF ANEMIA?
554. HEMOGLOBIN BART’S LEVELS IN CORD BLOOD OF BAHRAINI NEONATES AND ITS CORRELATIONS
WITH GENOTYPES OF ALPHA THALASSEMIA
555. THE HIGH FREQUENCY OF HB GROENE HART IN SPAIN: FIRST CASE OF ASSOCIATION OF THIS
VARIANT WITH HB J-PARIS-I
556. ASSOCIATION IN THE SAME GENE OF TWO MUTATIONS INTERFERING WITH BETA GLOBIN RNA
SPLICING IN A BETA MAJOR THALASSEMIC PATIENT.
557. ACERULOPLASMINEMIA IN A TURKISH ADOLESCENT WITH A NOVEL MUTATION OF CP GENE: THE
FIRST DIAGNOSED CASE FROM TURKEY
558. THE EFFECT OF IRON OVERLOAD ON THE RAT BONE MARROW ERYTHROBLAST DIFFERENTIATION
AND THE EXPRESSION OF IRON REGULATORY GENES
559. HB CIBELES [?LPHA2 CD25(B6)(GLY>ASP)]: A NOVEL ALFA CHAIN VARIANT CAUSING ALPHATHALASSEMIA
560. HAPLOTYPE ANALYSIS OF COMMON HFE MUTATIONS IN THE PORTUGUESE POPULATION AND
ASSOCIATION WITH IRON OVERLOAD
561. INVESTIGATION OF HEMORHEOLOGICAL PARAMETERS AT THE DIAGNOSIS AND FOLLOW UP OF
CHILDREN WITH IRON DEFICIENCY ANEMIA AND MIX ANEMIA
562. FLOW CYTOMETRIC TEST USING EOSINE-5 MALEIMIDE AS A FIRST-LINE SCREENING TEST
FOR DIAGNOSTICS OF HEREDITARY SPHEROCYTOSIS.
563. A NEW FRAMESHIFT MUTATION IN THE ?-GLOBIN GENE CAUSING ?0-THALASSEMIA: CD 47 (G)
564. A PRELIMINARY STUDY ON RISK OF A COUPLE HAVING A CHILD WITH SEVERE THALASSEMIA
SYNDROME, PREVALENCE IN KHON KAEN PROVINCE, THAILAND
565. GENETIC OF GLOBIN DISORDERS IN RUSSIA
566. SAFETY AND TOLERABILITY OF AUTOMATED RED CELL EXCHANGE TRANSFUSIONS IN PATIENTS
WITH SICKLE CELL DISEASE
567. LIVER DYSFUNCTION IN AN ADULT SICKLE COHORT
568. MYOCARDIAL AND HEPATIC IRON OVERLOAD IN SICKLE/THALASSEMIA PATIENTS OF ITALIAN
ORIGIN
569. UTILITY OF THE MULTIVARIATE APPROACH IN PREDICTING THE ?ETA-THALASSEMIA
INTERMEDIA OR MAJOR TYPES IN IRANIAN PATIENTS
570. BONE MARROW IRON ACCUMULATION IN SICKLE CELL DISEASE, PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA AND THALASSEMIA PATIENTS ASSESSED BY MRI
571. LONG-TERM EFFICACY OF DEFERASIROX FOR CARDIAC SIDEROSIS IN THALASSEMIA MAJOR
572. AUTOIMMUNE HAEMOLYTIC ANAEMIA IN MALIGNANT DISEASES
573. COMBINATION OF DEFERASIROX AND DEFEROXAMINE IN CLINICAL PRACTICE: ALTERNATIVE
SCHEMES OF CHELATION IN THALASSEMIA MAJOR (TM) PATIENTS
574. HEPATIC IRON CONCENTRATION QUANTIFICATION BY MRI: DIAGNOSIS AND MANAGEMENT IN
HEREDITARY HEMOCHROMATOSIS´S PATIENTS
575. TRANSIENT ELASTOGRAPHY TO ASSESS LIVER FIBROSIS IN PATIENTS WITH SICKLE CELL
DISEASE
576. QUALITY OF LIFE IN THALASSEMIA PATIENTS: ALMADINAH EXPERIENCE
577. CORTISOL RESPONSE TO LOW DOSE VERSUS STANDARD DOSE (BACK-TO-BACK)
ADRENOCORTICOTROPHIC STIMULATION TESTS IN CHILDREN AND YOUNG ADULTS WITH THALASSEMIA
MAJOR.
578. EVALUATION OF THE EFFECTIVENESS OF HEMOGLOBIN MEASURED BY A NON-INVASIVE
SPECTROPHOTOMETRIC PORTABLE DEVICE AS A SCREENING METHOD FOR ANEMIA DURING
PREOPERATIVE ASSESSMENT
579. EVALUATION OF QUALITY OF LIFE AND ANALYSIS OF EFFICACY AND SAFETY OF TWO IRON
CHELATORS IN PATIENTS WITH IRON OVERLOAD
580. PYRUVATE KINASE DEFICIENCY: CLINICAL AND MOLECULAR CHARACTERIZATION OF 11
PEDIATRIC CASES FROM ARGENTINA
581. HB RIAD/LAUSANNE, A NEW ?-VARIANT RESULTING FROM A DOUBLE MUTATION TGC >TCT,
(ALA>LEU), AT CODON 71. IDENTIFICATION BY CLONING AND SEQUENCING
582. EFFECT OF RHUEPO THERAPY ON LONG-TERM SURVIVAL OF ANEMIC CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKEMIA, UNDERGOING CHEMOTHERAPY
583. EPIDEMIOLOGICAL SURVEY OF ?LPHA-?HALASSAEMIA SYNDROMES IN NORTHERN GREECE
584. SCREENING PARADIGM FOR ?-THALASSEMIA CARRIERS; FROM CLINICAL TO MOLECULAR
585. EFFICACY OF RITUXIMAB IN AUTOIMMUNE HEMOLYTIC ANEMIA
586. THE EFFECT ON WEIGHT, BODY MASS INDEX AND SUBCUTANEOUS ADIPOSE TISSUE FAT OF
DIFFERENT CHELATING AGENT: A SURVEY FROM MIOT DATABASE
587. LONGITUDINAL MRI AND SERUM FERRITIN MONITORING OF IRON OVERLOAD IN CHRONICALLY
TRANSFUSED CHILDREN WITH HEMOGLOBINOPATHIES
588. RELATIONSHIP BETWEEN QT DISPERSION, PRO-BNP, T-WAVE ALTERNANS, HEART RATE
VARIABILITY AND BODY IRON BURDEN DETECTED BY THE FERRITIN, HEART AND LIVER MRI IN
ASYMPTOMATIC PATIENTS WITH THALASSEMIA MAJOR
589. STUDY OF THE ALTERATIONS OF PLATELET FUNCTIONS IN CHILDREN AND ADOLESCENTS WITH
IRON DEFICIENCY ANEMIA AND RESPONSE TO THERAPY
590. SUCCESSFUL CHELATION THERAPY WITH THE COMBINATION OF DEFERASIROX AND DEFERIPRONE
(3 PATIENTS) AND DEFEROXAMINE AND DEFERASIROX (2 PATIENTS).
591. PREGNANCY AND SICKLE CELL DISEASE: A SINGLE GREEK CENTER EXPERIENCE
592. FACTORS AFFECTING ANEMIA IN NORTHEAST THAI VEGANS
593. RENAL DYSFUNCTION MONITORING IN ADULT BETA-THALASSEMIC PATIENTS
594. MEDICAL RADIATION EXPOSURE IN SICKLE CELL DISEASE PATIENTS WITH FREQUENT
HOSPITAL ATTENDANCE FOR PAINFUL CRISES
595. CHALLENGES AND IMPACT OF INTRODUCING AN INTEGRATED CLINICAL PATHWAY AT
THALASSEMIA CENTRE – DUBAI
596. PARTNER TESTING FOR PREGNANT WOMEN AT RISK AND PRE-NATAL DIAGNOSIS OF SICKLE
CELL DISEASE. A SINGLE CENTRE 5 YEAR EXPERIENCE.
597. STUDY OF THE RENAL FUNCTIONS IN BETA (?)-THALASSEMIA (?-THALASSEMIA MAJOR, ?THALASSEMIA INTERMEDIA AND ?–THALASSEMIA MINOR) AND COMPARISON WITH THE TOTAL
ANTIOXIDANT CAPACITY
598. EVALUATION OF IMMUNE STATUS IN IRON DEFICIENCY ANEMIA
599. HIDDEN VITAMIN B12 DEFICIENCY
600. PREVALENCE OF 25-HYDROXYVITAMIN D DEFICIENCY IN KOREAN PATIENTS WITH ANEMIA
601. ORAL IRON CHELATION ENHANCES PYRIDOXINE EFFECT IN ONE PATIENT WITH INHERITED
SIDEROBLASTIC ANEMIA
602. ROLE OF IRON DEFICIENCY IN CHILDREN WITH THROMBOTIC EVENTS.
603. NEW INSIGHT ON IRON STUDY IN MYELODYSPLASIA
604. PRESCRIPTION OF APPROPRIATE OPIATE ANALGESIA AND OTHER ESSENTIAL MEDICATION FOR
PATIENTS WITH SICKLE CELL DISEASE PRESENTING WITH ACUTE VASOOCCLUSIVE CRISIS TO THE
EMERGENCY DEPARTMENT.
605. TOLERABILITY, SAFETY AND EFFICACY OF RECOMBINANT ERYTHROPOIETIN TREATMENT IN
PATIENTS WITH SICKLE CELL DISEASE: A SINGLE CENTRE EXPERIENCE.
606. THE 12 MONTHS FOLLOW-UP RESULTS FROM A COHORT OF PEDIATRIC PATIENTS WITH
HEMOGLOBINOPATHY AND USING ORAL IRON CHELATOR FOR TRANSFUSIONAL HEMOSIDEROSIS IN
TURKEY
607. NON- IRON DEFICIENCY ANEMIA IN PATIENTS WITH INFANTILE RICKETS
608. A COHORT STUDY TO ASSESS THE CONTRIBUTION OF PATIENT COMPLIANCE PROGRAM ON
PERSISTENCE TO DEFERASIROX IN PATIENTS WITH CHRONIC IRON OVERLOAD IN TURKEY (EX-PAT
PROGRAM)
609. EFFECT OF PATIENT EDUCATION ON IMPROVING KNOWLEDGE AND PRACTICES OF THALASSEMIC
ADOLESCENTS AT ZAGAZIG UNIVERSITY HOSPITAL
610. SUCCESSFUL LIVER TRANSPLANTATION IN SCD: CASE REPORT AND LITERATURE REVIEW
611. ASSESSMENT OF ERYTHROCYTE PHOSPHATIDYLSERINE EXPOSURE IN ?-THALASSEMIA
612. IRON OVERLOAD IN AN ADULT SICKLE CELL ANEMIA POPULATION
613. LONGITUDINAL STUDY ON THYROID FUNCTION IN PREPUBERTAL AND PUBERTAL PATIENTS WITH
THALASSEMIA MAJOR: HIGH INCIDENCE OF CENTRAL HYPOTHYROIDISM BY 18 YEARS
614. AUTOIMMUNE THYROID DYSFUNCTION IN YOUNG EGYPTIAN TRANSFUSION-DEPENDENT ?THALASSEMIA PATIENTS
615. BIOLOGICAL DIAGNOSIS OF THROMBOTIC THROMBOCYTOPENIC PURPURA: NOTHING BUT EYES?
616. LIPOSOMIAL IRON HAS AN ANTI-INFLAMMATORY EFFECT AND IS BETTER THAN IRON SULFATE
IN CORRECTION OF ANEMIA OF CHRONIC INFLAMMATORY DISEASE OF YOUNG WOMEN.
617. ELEVATED SERUM FERRITIN LEVELS >3,000 ?G/DL ARE HIGHLY ASSOCIATED WITH
ENDOCRINOPATHIES IN PATIENTS WITH THALASSEMIA
618. MISDIAGNOSIS OF HEMOGLOBIN D-PUNJAB/BETA THALASSEMIA IS A POTENTIAL PITFALL IN
HEMOGLOBINOPATHY SCREENING PROGRAMS: A CASE REPORT
619. CHANGES IN HAEMATOLOGICAL AND BIOCHEMICAL PARAMETERS IN PATIENTS WITH SICKLE
CELL DISEASE UNDERGOING AUTOMATED RED CELL EXCHANGE TRANSFUSIONS
620. HEMATOLOGICAL PROFILE BETWEEN PATIENTS WHO SUFFER FROM ISCHEMIC HEART DISEASE
AND PATIENTS WITH DILATED CARDIOMYOPATHY
621. FLOW CYTOMETRY QUANTITATIVE ANALYSIS OF HOWELL-JOLLY BODIES IN CHILDREN WITH
CHRONIC HEMOLYTIC ANEMIA
622. RETROSPECTIVE STUDY OF IRON DEFICIENCY ANEMIA IN HEMATOLOGY CLINIC
623. DIAMOND-BLACKFAN ANEMIA: A CENTER EXPERIENCE
624. MACROCYTIC ANEMIA AND ITS CAUSES: A PROSPECTIVE COHORT STUDY
625. TRANSCRANIAL DOPPLER IMAGING IN THE MANAGEMENT OF PEDIATRIC SICKLE CELL DISEASE
PATIENTS: IMPACT OF HYDROXYUREA
626. IRON AND VITAMIN D STATUS IN EXCLUSIVELY BREAST-FED INFANTS UNDER 24 MONTHS AND
LACTATING MOTHERS
627. MAY BE PREDICTED THE PATIENTS WITH IRON DEFICIENCY WITHOUT ANEMIA FROM
PARAMETERS OF COMPLETE BLOOD COUNT?
628. MANAGEMENT OF INVASIVE FUNGAL INFECTIONS IN PEDIATRIC ACUTE LEUKEMIA AND THE
APPROPRIATE TIME FOR RESTARTING CHEMOTHERAPY
629. RISK FACTORS FOR ACQUIRED BLOODSTREAM INFECTION AMONG NEUTROPENIC PATIENTS.
630. POSACONAZOLE PROPHYLAXIS DURING INTENSIVE CHEMOTHERAPY FOR ACUTE MYELOID
LEUKEMIA (AML): RESULTS OF A PROSPECTIVE AUDIT OF 102 PATIENT EPISODES
631. PERIPHERALLY INSERTED CENTRAL CATHETERS IN PATIENTS WITH HEMATOLOGICAL DISEASES:
A RETROSPECTIVE STUDY
632. ROLE OF SEDO-ANALGESIA IN EXECUTION OF BONE MARROW BIOPSIES
633. EPIDEMIOLOGY OF BLOODSTREAM INFECTION IN FEBRILE ADULTS WITH HEMATOLOGICAL
CANCER
634. HAND HYGIENE AUDIT AT THALASSEMIA CENTRE-DUBAI
635. A NOVEL FRAGILITY MARKER OF RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION : PERITRANSPLANT CMV VIREMIA
636. FEBRILE NEUTROPENIA EPISODES AND EVALUATION OF AVAILABLE BIOMARKERS AMONG
CHILDREN WITH HEMATOLOGICAL MALIGNANCIES
637. PROCALCITONIN AND C-REACTIVE PROTEIN AS PREDICTIVE PARAMETERS FOR DEVELOPING
SEVERE SEPSIS IN FEBRILE NEUTROPENIA.
638. BONE MARROW ALTERATIONS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV)
INFECTION IN THE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) ERA, IN A HIGH
COMPLEXITY UNIVERSITY HOSPITAL IN BOGOTA, COLOM
639. EFFICACY OF POSACONAZOLE PROPYLAXIS IN AML INDUCTION THERAPY, SINGLE CENTER
EXPERIENCE
640. THE RELATIONSHIP BETWEEN LEVELS OF SERUM MANNOSE-BINDING PROTEIN AND
BACTERIEMIA/SEPSIS IN FEBRILE NEUTROPENIC CHILDREN WITH CANCERS
641. COMPARISON OF THE SIDE EFFECTS OF ANTIBIOTICS IN PATIENTS WITH THE DIAGNOSIS OF
FEBRILE NEUTROPENIA
642. FEBRILE NEUTROPENIA: INCIDENCE, FOCI OF INFECTION, AND UNDERLYING
MICROBIOLOGICAL PATHOGENS
643. VISCERAL LEISHMANIASIS ASSOCIATED HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A CAREFUL
BALANCING ACT
644. HEPATO-SPLENIC NECROTIC NODULES WITH NORMAL HEPATIC ENZYMES AND HEPATIC
SYNTHETIC FUNCTION - AN UNUSUAL PRESENTATION OF ADENOVIRAL INFECTION AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION
645. MICAFUNGIN FOR ANTIFUNGAL PROPHYLAXIS IN PATIENTS UNDERGOING AUTOLOGOUS STEM
CELL TRANSPLANTATION
646. REAL LIFE EXPERIENCE OF ANTI-FUNGAL PROPHYLAXIS WITH POSACONAZOLE IN PATIENTS
WITH ACUTE LEUKEMIA AT A SINGLE CENTER LACKING HEPA-FILTER
647. INCIDENCE, MORTALITY AND CAUSATIVE PATHOGENS OF SEPTIC SHOCK IN NEUTROPENIC
PATIENTS AFTER INTENSIVE CHEMOTHERAPY
648. THE DEFEAT OF THE COLON BY HEMOBLASTOSES: CLINICAL, ENDOSCOPIC,
IMMUNOHISTOCHEMICAL FEATURES AND OPTIMIZATION OF TREATMENT
649. THE EFFICACY OF PALONOSETRON IN MANAGING SYMPTOMS INDUCED BY HIGH AND MODERATE
EMETOGENIC CHEMOTHERAPY-THE EXPERIENCE OF FUNDENI CLINIC OF HEMATOLOGY
650. COMPARISON OF ANTIFUNGAL AGENTS EFFECTS AND SIDE EFFECTS IN NEUTROPENIC FEVER
ATTACKS
651. EFFECT OF BLOOD DONATIONS ON IRON STORES OF BLOOD DONORS
652. CERTIFICATION AND EDUCATION PROGRAM. HOW TO IMPROVE QUALITY MARKERS OF
TRANSFUSION THERAPY IN HOSPITAL
653. EVALUATION OF APOPTOSIS MARKER AT THE MEMBRANE SURFACE OF RESIDUAL LYMPHOCYTES
IN GAMMA-IRRADIATED PLATELET CONCENTRATES
654. ACUTE EFFECTS OF BLOOD TRANSFUSION ON LEFT CARDIAC FUNCTIONS AND CARDIAC MARKERS
IN WELL-TREATED THALASSEMIA MAJOR PATIENTS
655. AUDIT AND REAUDIT OF WEARING IDENTIFICATION WRISTBAND DURING BLOOD TRANSFUSION
AT DUBAI THALASSEMIA CENTER
656. POSTTRANSFUSION PLATELET RESPONSE IN HEMATOLOGICAL INPATIENTS
657. CLINICAL EXPERIENCE OF GRANULOCYTE TRANSFUSION IN THE MANAGEMENT OF PEDIATRIC
PATIENTS WITH FEBRILE NEUTOPENIA: A RETROSPECTIVE STUDY FROM A REFERENCE CENTER IN
TURKEY
658. PLATELET EXPENDITURE IN HEMATOLOGY PATIENTS
659. USE OF RECOMBINANT FACTOR VIIA (RFVIIA) IN ACUTE LIFE THREATENING PRIMARY
POSTPARTUM HAEMORRHAGE: A CASE REPORT
660. PHENOTYPE FREQUENCIES OF BLOOD GROUP SYSTEMS AND ALLOANTIBODIES TO RED BLOOD
CELLS IN BLOOD RECIPIENTS IN CENTRAL ANATOLIA OF TURKEY
661. CORRELATION BETWEEN ABO BLOOD TYPE AND THE SITE OF CANCER
662. CLINICAL OUTCOMES OF ABO INCOMPATIBLE RBC TRANSFUSIONS
663. COMBINATION OF DEFERASIROX AND DEFEROXAMINE IN MANAGEMENT OF IRON OVERLOAD IN
MYELODYSPLASTIC SYNDROMES (MDS): AN UPDATE IN A HEPATOPATIC PATIENT
664. COMPARATIVE STUDY OF DEFERRED BLOOD DONORS CHARACTERISTICS- HOW THEY CORRELATE
WITH WHERE THE BLOOD DONATION TOOK PLACE (HOSPITAL OR MOBILE UNITS)
665. EOSINOPHILIC FASCIITIS
666. NEUTROPAENIA FOUND ON ROUTINE LABORATORY TESTING – IS FOLLOW-UP REQUIRED?
667. THE CLINICAL FEATURES AND GENETIC MUTATIONS OF CHRONIC GRANULOMATOUS DISEASE:
RESULTS FROM A REFERENCE CENTRE AT MIDDLE ANATOLIA
668. THE COINCIDENCE OF FAMILIAL MEDITERRANEAN FEVER AND HYPEREOSINOPHILIA IN A
PATIENT WITH HEREDITARY ELLIPTOCYTOSIS
669. HYPEREOSINOPHILIC SYNDROME: CASE REPORT
670. TYPE I GAUCHER´S DISEASE: CLINICAL, EVOLUTIVE AND THERAPEUTIC FEATURES
671. THE CLINICAL SIGNIFICANCE OF PLATELET INDICES IN PATIENTS WITH SEPSIS
672. RITUXIMAB THERAPY IN REFRACTORY AND RELAPSED THROMBOTIC THROMBOCYTOPENIC
PURPURA; A RETROSPECTIVE ANALYSIS OF A SINGLE CENTRE IN QATAR
673. A STUDY OF 100 EGYPTIAN CHILDREN WITH INHERITED PLATELET DISORDERS:AN
UNDERESTIMATED AND UNDERDIAGNOSED PROBLEM
674. SINGLE CENTRE EXPERIENCE OF THROMBOTIC EVENTS IN PATIENTS TREATED WITH
ROMIPLOSTIM
675. RETROSPECTIVE EVALUATION OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA PATIENTS
676. ATYPICAL PRESENTATION OF UPSHAW-SCHULMAN SYNDROME IN A PREGNANT PATIENT WITH
OMOZYGOUS FOR V LEIDEN MUTATION
677. AN INVESTIGATION OF PLATELET DISORDERS IN PATIENTS WITH SUBCLINICAL
HYPOTHYROIDISM
678. EVALUATION OF AFFECTING FACTORS FOR PLATELET FUNCTION SCREENING TEST
679. TREATMENT OF REFRACTORY KASABACH-MERRITT PHENOMENON WITH SIROLIMUS
680. VENOUS THROMBOEMBOLIC EVENTS IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) PATIENTS
AFTER SPLENECTOMY OR DURING THROMBOPOIETIN RECEPTOR AGONISTS (TPORA) THERAPY
681. PERSISTENT REMISSION OF CHRONIC IMMUNE THROMBOCYTOPENIA AFTER ROMIPLOSTIM
DISCONTINUATION
682. A CASE OF MYH9 DISORDER WITH KIDNEY DYSFUNCTION SUCCESSFULLY TREATED BY
ELTROMBOPAG FOR THE?INHERITED THROMBOCYTOPENIA
683. THE EFFECTIVNES AND SAFETY OF THE THROMOPOETIN(TPO) RESEPTOR AGONISTS IN THE
TREATMENT OF ADULTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA(ITP) REFRACTORY TO OTHER
TREATMENTS
684. REFRACTORY CYCLIC THROMBOCYTOPENIA
685. THROMBOCYTOPENIA DURING LONG-TERM LOW-MOLECULAR-WEIGHT HEPARINS (LMWH) FOR
CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM (VTE): TROPIQUE, A PROSPECTIVE, MULTICENTER,
OBSERVATIONAL STUDY
686. SLOW “DELAYING AND TAPERING” ROMIPLOSTIM ADMINISTRATION COULD ALLOW ITS
DEFINITIVE SUSPENSION AND STABLE COMPLETE REMISSION IN PRIMARY IMMUNE
THROMBOCYTOPENIA (ITP) PATIENTS
687. SUCCESSFUL TREATMENT WITH THE TPO AGONIST ROMIPLOSTIM OF A YOUNG PATIENT WITH
MYH9 RELATED THROMBOCYTOPENIA
688. A COMPARATIVE STUDY OF NEW PLATELET INDICES IN PATIENTS WITH IRON DEFICIENCY AND
HOMOZYGOUS OR HETEROZYGOUS SICKLE CELL DISEASE
689. COMPARISON OF MANUAL AND AUTOMATED PLATELET COUNTS IN THROMBOCYTOPENIA
690. SAME DIAGNOSIS, DIFFERENT PROBLEMS, VARIABLE CLINICAL PROGRESS: IMPRESSIONS
RELATING TO ELTROMBOPAG TREATMENT WITH 4 CASES
691. PSEUDOTHROMBOCYTOPENIA ASSOCIATED WITH GRAVES’ DISEASE
692. CORRELATION BETWEEN PLATELET ACTIVATION INDICES AND METABOLIC PARAMETERS.
693. EFFICACY AND SAFETY OF TPO-R AGONIST IN NEUROSURGICAL SETTING: SUCCESSFULLY
PERIOPERATIVE ROMIPLOSTIM TREATMENT OF A THROMBOCYTOPENIC PATIENT UNRESPONSIVE TO
FIRST LINE THERAPY
694. RETROSPECTIVE ANALYSIS OF THERAPEUTICAL RESULTS IN IMMUNE THROMBOCYTOPENIC
PURPURA
695. THE EFFICACY OF REVOLADE(ELTROMBOPAG) IN IDIOPATHIC AUTOIMMUNE THROMBOCYTOPENIC
PURPURA(ITP)-SINGLE CENTER EXPERIENCE:
696. THE ANTIPHOSPHOLIPID ANTIBODIES, A RISK FACTOR TO DEVELOPED ANTIPHOSPHOLIPIDE
SYNDROME OR SYSTEMIC LUPUS ERYTHEMATOUS IN THE PATIENTS WITH IMMUNE THROMBOCYTOPENIC
PURPURA (ITP)
697. MANAGEMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) THERAPY - A RESTROSPECTIVE
STUDY ON 49 PATIENTS
698. THE RESULTS OF THE SAUDI NATIONAL SCREENING PROGRAM FOR FACTOR VIII AND IX
HEMOPHILA INHIBITORS
699. LARGE INTER-INDIVIDUAL VARIABILITY OF THE RESPONSE TO NEW ORAL ANTICOAGULANTS
700. POLYMORPHISM OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR AND RISK OF
INTRACRANIAL HEMORRHAGE IN FACTOR XIII DEFICIENCY
701. THROMBIN GENERATION TEST FOR IDENTIFICATION OF PATIENTS AT HIGH THROMBOTIC OR
BLEEDING RISK
702. NOVEL ORAL ANTICOAGULANTS - PROTOCOL TO MINIMISE BLEEDING AND EDUCATE DENTAL
SURGEONS
703. MANAGEMENT OF DENTAL INVASIVE PROCEDURES IN HEMOPHILIA A/B AND VON WILLEBRAND
DISEASE OUTPATIENTS
704. PROPHYLAXIS WITH ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (FEIBA) IN CHILDREN
WITH SEVERE HAEMOPHILIA A (HAEMA) AND HIGH RESPONDING FVIII INHIBITORS BEING ON
IMMUNE TOLERANCE INDUCTION (ITI)
705. THE SIGNIFICANCE OF TEG AND TGA IN THE EVALUATION OF HEMOSTASIS IN CHILDREN WITH
CYANOTIC AND ACYANOTIC CONGENITAL HEART DISEASES
706. INTRACRANIAL HEMORRHAGE IN HEREDITARY BLEEDING DISORDERS: THE EXPERIENCE OF
ÇUKUROVA
707. HEMATURIA IN CONGENITAL COAGULATION FACTOR DEFICIENCIES
708. MAJOR SURGICAL INTERVENTIONS IN CHILDHOOD RARE FACTOR DEFICIENCIES:A SINGLECENTER EXPERIENCE FROM TURKEY
709. RECURRENT NEONATAL INTRACRANIAL HEMORRHAGE AS THE SOLE INITIAL PRESENTING
SYMPTOM OF ACQUIRED FACTOR II DEFICIENCY: A CASE REPORT IN AN EGYPTIAN CHILD WITH
TYROSINEMIA TYPE 1
710. A CASE STUDY OF POSTPARTUM HEMOPHILIA: HETEROGENICITY IN CLINICAL PRESENTATION,
THERAPY REQUIREMENTS AND THERAPY ADVERSE EFFECTS
711. ILIOPSOAS HEMORRHAGE IN CONGENITAL FACTOR DEFICIENCIES:THE EXPERIENCE OF
ÇUKUROVA UNIVERSITY, ADANA , TURKEY
712. OUR CASES DIAGNOSED AS HEMORRHAGIC DISEASE OF THE NEWBORN
713. PERCUTANEOUS TRANSLUMINAL AORTIC VALVE IMPLANTATION (TAVI) FOR SEVERE AORTIC
VALVE STENOSIS IN PATIENT WITH HEMOPHILIA A
714. TRANEXAMIC ACID AS PROPHYLAXIS IN A YOUNG HAEMOPHILIA PATIENT WITH INHIBITOR
PRESENCE
715. PERCUTANEUS TRANSLUMINAL ANGIOPLASTY (PTA) FOR AORTIC COARCTATION (COA) IN
PATIENT WITH HEMOPHILIA A AND HIGH INHIBITORS TITRE USING FACTOR VIII INHIBITOR
BYPASS ACTIVITY (FEIBA®)
716. FOLLOW-UP AND PROGRESSION OF HEMOPERITONEUM DEVELOPED IN A TYPE 3 VON WILLEBRAND
PATIENT SECONDARY TO THE HEMORRHAGIC RUPTURE OF CORPUS LUTEUM
717. EXPERIENCE WITH PROTHROMBIN COMPLEX CONCENTRATES FOR PROPHLAXIS AND TREATMENT OF
BLEEDING
718. SPONTANEOUS DUODENAL HEMATOMA IN A PATIENT WITH GLANZMANN’S THROMBASTHENIA
719. PROTEIN C SERUM LEVELS ARE DECREASED IN HEART FAILURE: A GLIMPSE AT THE
PULMONARY SIDE OF THE EQUATION?
720. THROMBOEMBOLISM PROPHYLAXIS AFTER CESAREAN SECTION (PRO-CS) TRIAL
721. THROMBELASTOMETRY IN DUAL ANTIPLATELET TREATMENT IN PATIENTS WITH ACUTE CORONARY
SYNDROME
722. CONTRIBUTORY RISK FACTORS FOR DEVELOPMENT OF THROMBOSIS IN CHILDREN WITH
NEPHROTIC SYNDROME
723. FIBRINOGEN GENETIC VARIABILITY AND PROTHROMBOTIC PROFILE IN PATIENTS WITH
HYPERTENSION
724. IDIOPATHIC PURPURA FULMINANS, DIFFERENTIAL DIAGNOSIS OF CUTANEOUS THROMBOSIS IN
CHILDHOOD, ANTITHROMBOTIC THERAPY AND MONITORING
725. MONITORING OF LOW-MOLECULAR-WEIGHT HEPARIN IN HIGH RISK PREGNANCY
726. THROMBIN-LIKE AMIDASE ACTIVITY IN PLASMA REMAINS HIGH AFTER LUNG DISEASES
EXACERBATIONS
727. STUDY OF CONSTITUTIONAL THROMBOTIC RISK FACTORS AND ACQUIRED RETINAL VEIN
THROMBOSIS. EXPERIENCE A CENTER.
728. EVALUATION OF HEALTH LITERACY AND ADHERENCE TO THROMBOPROPHYLAXIS IN PREGNANCY
729. LOCAL EXPERIENCE IN THE DIAGNOSIS AND TREATMENT OF DEEP PELVIC SEPTIC
THROMBOPHLEBITIS
730. THROMBOPHILIC STATUS IN PATIENTS WITH EXTRA-HEPATIC PORTAL HYPERTENSION
731. THROMBOPHILIC RISK FACTORS AND THE EFFICIENCY OF PROPHYLACTIC ANTICOAGULATION
THERAPY IN CHILDREN WHO UNDERWENT RENAL TRANSPLANTATION
732. ANTITHROMBOTIC PREVENTION IN NEUROSURGERY
733. DEEP VENOUS THROMBOSIS SECONDARY TO MAY-THURNER SYNDROME: A CASE REPORT
734. WARFARIN-INDUCED BREAST NECROSIS ASSOCIATED WITH FV LEIDEN, PROTEIN S DEFICIENCY
AND PROTHROMBIN G20210A MUTATION
735. THROMBOSIS PREDICTORS IN SAUDI PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A
PRELIMINARY STUDY
736. LIPOPROTEIN(A) AND ISCHEMIC STROKE IN CHILDREN: A SINGLE CENTER EXPERIENCE IN
SOUTH AMERICA
737. THE INCIDENCE OF VENOUS THROMBOEMBOLISM IN UNSELECTED MYELOMA PATIENTS ATTENDING
A TERTIARY REFERRAL CENTRE
738. EXCESS BLOOD CLOTTING FACTOR VIII AND THE RISK OF THE INFRINGEMENT OF CEREBRAL
CIRCULATION
739. TO ADMIT OR NOT TO ADMIT HEMATOLOGIC PATIENTS IN THE ICU? THAT’S THE QUESTION!
740. METRONOMIC THERAPHY IN VERY OLD PATIENTS : WHEN TO TREAT AT HOME BED IT’S NOT SO
BAD.
741. IMPROVEMENT OF QUALITY OF LIFE AND INCREASE HEMOGLOBIN CONCENTRATION IN ANEMIC
PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS TREATED ERYTHROPOIESIS-STIMULATING AGENTS
742. DISSOCIATIVE DISORDERS IN STRUCTURE OF PSYCHOGENIC REACTIONS AT THE BLOOD SYSTEM
DISEASES PATIENTS
743. HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY IMPACT OF MYELODYSPLASTIC
SYNDROMES (MDS): THE PATIENT PERSPECTIVE
744. AUDIT MORTALITY WITHIN 30 DAYS OF CHEMOTHERAPY IN A DISTRICT GENERAL HOSPITAL
IN UK
745. QUALITY OF LIFE AND DISEASE UNDERSTANDING: IMPACT OF ATTENDING A PATIENT
CENTERED CANCER SYMPOSIUM
746. THE FACTORS OF KETAMINE THAT AFFECT SEDATION IN CHILDREN WITH
HEMATOLOGY/ONCOLOGY PROCEDURES: PARENT SATISFACTION PERSPECTIVE
747. IMPACT OF HYPOMETHYLATING AGENTS ON THE BLOOD PRESSURE OF THE PATIENT WITH
HEMATOLOGIC MALIGNANCIES: SAFETY AND RECOMMENDATIONS FOR USE.
748. SECOND PRIMARY MALIGNANCY IN HEMATOLOGY PATIENTS IS A RARE ENTITY?
749. ROMANIAN PEOPLES OPINION ABOUT THE UTILITY OF CHEMOTHERAPY IN ACUTE LEUKEMIC
PATIENTS
750. PALLIATIVE CARE FOR CHILDHOOD CANCER IN COUNTRIES WITH LIMITED HEATH RESOURCES:
CURRENT CHALLENGES
751. THE COST OF PRODUCING A UNIT OF BLOOD IN GREECE: AN ECONOMIC ANALYSIS FOR THE
CASE OF “AGIOS SAVVAS” REGIONAL CANCER HOSPITAL
752. UNDERSTANDING PATTERNS OF ORDERING COMMON BLOOD TESTS IN PATIENTS ADMITTED TO
HOSPITAL – AN AUDIT TO EVALUATE NUMBER AND FREQUENCY OF COMMON BLOOD TESTS IN
ADMITTED PATIENTS IN A MEDIUM SIZED DGH
753. WORTHINESS OF BONE MARROW TRANSPLANTATION AS A TREATMENT OPTION FOR THALASSEMIA
PATIENTS IN DEVELOPING COUNTRIES
754. SURVIVAL AND TREATMENT RELATED DEATHS IN PEDIATRIC ONCOLOGY PATIENTS: A SINGLE
CENTER RETROSPECTIVE COHORT STUDY
755. MORBIDITY RATE OF MALIGNANT NEOPLASMS OF LYMPHOID AND HEMATOPOIETIC TISSUE IN
SAINT PETERSBURG
756. GOOD SURVIVAL RATES IN ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA COME
AT A PRICE
757. A PROSPECTIVE STUDY ON THE COST AND UTILIZATION OF AZACITIDINE IN A CANADIAN
PROVINCE: IMPLICATIONS FOR BUDGET IMPACT ANALYSIS (BIA)
758. OVARIAN FUNCTION IN FEMALE SURVIVORS OF CHILDHOOD MALIGNANCIES
759. CHEMOTHERAPY ORDERING, PREPARATION AND ADMINISTRATION USING COMPUTERIZED OREDR
ENTRY SYSTEM – HOSPITAL AMPANG (MALAYSIA) EXPERIENCE
760. EVALUATION OF SERUM LEVELS OF MULTIPLE CYTOKINES AND ADHESION MOLECULES IN
PATIENTS TREATED FOR ACUTE MYELOID LEUKEMIA
761. PREDICTION OF CLINICAL RESPONSE USING A PERSONALIZED MEDICINE EX VIVO TEST IN A
PATIENT DIAGNOSED WITH MIXED PHENOTYPE T/MYELOID ACUTE LEUKEMIA
762. SERUM FREE LEPTIN, LEPTIN RECEPTOR AND INSULIN IN RELATION TO B-CELL CHRONIC
LYMPHOCYTIC LEUKEMIA RISK
763. THE RESPONSE TO CHEMOTHERAPY AND IMMUNOCHEMOTHERAPY AMONG PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKEMIA ACCORDING TO THE NUMBER OF CELLS WITH A DELETION OF 13Q14
764. SERUM FETUIN-A/?2HS-GLYCOPROTEIN LEVELS IN PATIENTS WITH B-CELL CHRONIC
LYMPHOCYTIC LEUKEMIA
765. THE POTENTIAL ROLE OF DEXA-BEAM IN MULTIPLE MYELOMA FOCUSING ON EXTRAMEDULLARY
DISEASE – A CASE SERIES
766. COMPASSIONATE USE PROGRAM (CUP) WITH RUXOLITINIB IN PATIENTS WITH PRIMARY
MYELOFIBROSIS (PMF), POST–POLYCYTHEMIA VERA MYELOFIBROSIS (PPV–MF), AND POST–
ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
767. SAFETY PROFILE OF RUXOLITINIB IN PRIMARY MYELOFIBROSIS, POST -POLYCITEMIA VERA
MYELOFIBROSIS AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN A COMPASSIONATE USE
PROGRAM (CUP) IN MEXICO
768. EFFICACY AND SAFETY OF THERAPY WITH 90Y IBRITUMOMAB TIUXETAN, IN B CELL NHL
PATIENTS OVER 65 YEARS OLD.
769. ALLOGENEIC VERSUS AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON
PROMYELOCYTIC ACUTE MYELOID LEUKEMIA: 30 YEARS EXPERIENCE IN A SINGLE CENTER
770. LOCAL RENIN-ANGIOTENSIN SYSTEM IN NORMAL HEMATOPOIETIC AND MULTIPLE MYELOMA-
RELATED PROGENITOR CELLS
771. LOCAL HEMATOPOIETIC RENIN-ANGIOTENSIN SYSTEM IN MYELOID VERSUS LYMPHOID
HEMATOLOGICAL NEOPLASTIC DISORDERS
772. DEEP SEQUENCING REVEALS SMALL SUBCLONES OF STAT3 MUTATIONS IN LARGE GRANULAR
LYMPHOCYTIC LEUKEMIA